

# Wetenschappelijk overzicht IKNL 2025

Alle publicaties zijn op te vragen via [bibliotheek@iknl.nl](mailto:bibliotheek@iknl.nl)

# Inhoudsopgave

<b>1</b>	<b>Niet-tumorspecifiek</b>	<b>3</b>
	1.1 Publicaties met impactfactor	3
	1.2 Overige publicaties	8
	1.3 Proefschriften en promoties	8
<b>2</b>	<b>Borstkanker</b>	<b>10</b>
	2.1 Publicaties met impactfactor	10
	2.2 Overige publicaties	14
	2.3 Proefschriften en promoties	14
<b>3</b>	<b>Bot-en wekedelentumoren</b>	<b>15</b>
	3.1 Publicaties met impactfactor	15
<b>4</b>	<b>Darmkanker</b>	<b>16</b>
	4.1 Publicaties met impactfactor	16
	4.2 Overige publicaties	18
	4.3 Proefschriften en promoties	18
<b>5</b>	<b>Gynaecologische tumoren</b>	<b>19</b>
	5.1 Publicaties met impactfactor	19
	5.2 Proefschriften en promoties	20
<b>6</b>	<b>Hemato-oncologie</b>	<b>21</b>
	6.1 Publicaties met impactfactor	21
<b>7</b>	<b>Hoofdhalskanker</b>	<b>24</b>
	7.1 Publicaties met impactfactor	24
<b>8</b>	<b>Huidkanker</b>	<b>25</b>
	8.1 Publicaties met impactfactor	25
<b>9</b>	<b>Longkanker</b>	<b>26</b>
	9.1 Publicaties met impactfactor	26
<b>10</b>	<b>Neuro-oncologie</b>	<b>28</b>
	10.1 Publicaties met impactfactor	28
<b>11</b>	<b>Upper GI &amp; HPB</b>	<b>29</b>
	11.1 Publicaties met impactfactor	29
	11.2 Overige publicaties	32
	11.3 Proefschriften en promoties	32
<b>12</b>	<b>Urogenitale kanker</b>	<b>33</b>
	12.1 Publicaties met impactfactor	33
	12.2 Proefschriften en promoties	35
<b>B1</b>	<b>Impactfactoren tijdschriften</b>	<b>36</b>

# 1 Niet-tumorspecifiek

## 1.1 Publicaties met impactfactor

Albers EA, de Ligt KM, van der Ploeg IM, Wouters MJ, Schagen SB, **van de Poll-Franse LV**. Screening for cognitive impairment in routine clinical oncology practice: a pilot study using patient-reported outcome measures and online cognitive testing in melanoma and breast cancer patients. *Support Care Cancer*. 2025 Mar 12;33(4):273. doi: 10.1007/s00520-025-09325-9. Impactfactor: 3,0

Allemani C, Minicozzi P, Morawski B, Lima CA, Bennett D, Pongnikorn D, Petrova D, Innos K, Girardi F, Galán Alvarez Y, Schaffar R, Dal Maso L, Molinié F, Valkov M, Phillips K, **Siesling S**, Schultz A, Daubisse-Marliac L, Marcos-Gragera R, Di Carlo V; VENUSCANCER Working Group. Global variation in patterns of care and time to initial treatment for breast, cervical, and ovarian cancer from 2015 to 2018 (VENUSCANCER): a secondary analysis of individual records for 275 792 women from 103 population-based cancer registries in 39 countries and territories. *Lancet*. 2025 Oct 22:S0140-6736(25)01383-2. doi: 10.1016/S0140-6736(25)01383-2. Online ahead of print. Impactfactor: 88,5

**Bastings D**, Schermer T, **van Roij J**, van den Beuken-Everdingen MH, Hendriks MP, van Laarhoven HW, Mandigers C, Smilde TJ, Sommeijer DW, Tromp C, Vriens B, **Raijmakers NJ**; eQuiPe Study Group. Emotional supportive care needs in patients with advanced cancer and their associated characteristics: a multicenter observational cohort Study (eQuiPe Study). *J Palliat Med*. 2025 Feb 19. doi: 10.1089/jpm.2024.0142. Online ahead of print. Impactfactor: 2,1

Boekel NB, **Verloop J**, van Boven HH, van Erp EJ, Schrijver L, Rookus MA, van Leeuwen FE. Cancer risk after in utero exposure to diethylstilbestrol. *Eur J Epidemiol*. 2025 May 28. doi: 10.1007/s10654-025-01234-9. Online ahead of print. Impactfactor: 5,9

Botta L, Didonè F, Lopez-Cortes A, Nieto AC, Desandes E, Hjalgrim LL, Jakab Z, Stiller CA, Zeller B, Gatta G, Pritchard-Jones K; BENCHISTA Project Working Group (**Visser O, Karim-Kos H**). International benchmarking of stage at diagnosis for six childhood solid tumours (the BENCHISTA project): a population-based, retrospective cohort study. *Lancet Child Adolesc Health*. 2025 Feb;9(2):89-99. doi: 10.1016/S2352-4642(24)00302-X. Impactfactor: 15,5

Botta L, Capocaccia R, Bernasconi A, Rossi S, Galceran J, Dal Maso L, Lepage C, Molinié F, Bouvier AM, Marcos-Gragera R, Vener C, Guevara M, Murray D, Ragusa R, Gatta G, Jooste V; EUROCORE-6 WG (**Visser O, Siesling S**). The impact of cancer survivors' extra risk of noncancer mortality on net survival estimation. *Am J Epidemiol*. 2025 Nov 4;194(11):3316-3324. doi: 10.1093/aje/kwaf148. Impactfactor: 4,8

Bouma R, Stegmann ME, **Raijmakers NJ**, van Zuylen L, Reyners AK, van Asselt K, van Gastel MD, Brandenburg D, Geerse OP. Defining patients living long-term with incurable cancer: a modified hybrid Delphi study. *Palliat Med*. 2025 Dec 26:2692163251400114. doi: 10.1177/02692163251400114. Online ahead of print. Impactfactor: 3,9

**Breed FF**, Breed WP, Dercksen MW, **Ezendam NP, Bijlsma MJ, van den Hurk CJ**. Shorter post-infusion cooling times at least as effective as longer cooling times: an observational study of taxane- and anthracycline-based chemotherapies in the Dutch Scalp Cooling Registry. *Support Care Cancer*. 2025 May 28;33(6):503. doi: 10.1007/s00520-025-09526-2. Impactfactor: 3,0

**de Heus E**, Husson O, **Zwaan E, Oerlemans S, Mols F, Ezendam NP, Duijts SF**. The role of health literacy in perceived information provision, satisfaction, and health-related quality of life among rare and common cancer patients: a population-based registry study. *J Cancer Educ*. 2025 Nov 5. doi: 10.1007/s13187-025-02768-y. Online ahead of print.

Impactfactor: 1,3

**de Korte AM, van Deursen L**, van der Lee ML, Aardoom JJ, **Ezendam NP**, Heine P, **Mols F**, Mulder-Mertens H, **Stouten MM, Lammens CR**. Implementation of the eHealth Appstore to improve access to self-management applications for Dutch people directly affected by cancer and their relatives: study protocol. *Support Care Cancer*. 2025 Jul 5;33(7):660. doi: 10.1007/s00520-025-09720-2. Impactfactor: 3,0

**de Korte AM, van Deursen L**, van der Lee ML, Aardoom JJ, **Ezendam NP**, Heine P, **Mols F**, Mulder-Mertens H, **Stouten MM, Lammens CR**. Who uses self-management apps from the OncoAppstore: description of characteristics, symptoms, and functioning of a real-world user population. *J Cancer Surviv*. 2025 Jul 5. doi: 10.1007/s11764-025-01855-9. Online ahead of print. Impactfactor: 2,9

de Ligt KM, Hommes S, Vromans RD, Boomstra E, **van de Poll-Franse LV**, Kraemer EJ. Improving the implementation of patient-reported outcome measure in clinical practice: tackling current challenges with innovative digital communication technologies. *J Med Internet Res*. 2025 Feb 5;27:e60777. doi: 10.2196/60777. Impactfactor: 6,0

de Vries S, Francke K, Vervoort S, Pijnappel L, Milota M, **van der Linden Y**, Teunissen S, de Graaf E. Prioritizing the values, wishes, and needs of patients with advanced cancer: a secondary linguistic analysis. *Health Commun*. 2025 Feb 11:1-9. doi: 10.1080/10410236.2025.2462065. Online ahead of print. Impactfactor: 2,7

**Dinnessen R, Beijer S, Oerlemans S**, Husson O, **Mols F**, Bours MJ, **Ezendam NP**. Sleep quality and overall survival among cancer survivors in the Netherlands: a PROFILES registry study. *Sleep Med*. 2025 Apr 2;131:106488. doi: 10.1016/j.sleep.2025.106488. Online ahead of print. Impactfactor: 3,4

Farrugia T, **Duijts SF**, Cockburn C, Hemming L, Wilson C, Spelten E. 'I knew I had to drive my own bus': perspectives of patients and healthcare professionals on improving information provision to rare cancer survivors. *J Cancer Surviv*. 2025 Sep 19. doi: 10.1007/s11764-025-01896-0. Online ahead of print. Impactfactor: 2,9

Forjaz G, Kohler B, Coleman MP, Steliarova-Foucher E, Negoita S, Guidry Auvil JM, Michels FS, Goderre J, Wiggins C, Durbin EB, **Geleijnse G**, Henrion MC, Altmayer C, Dubois T, Penberthy L. Making the case for an international childhood cancer data partnership. *J Natl Cancer Inst*. 2025 Jan 12:djaf003. doi: 10.1093/jnci/djaf003. Online ahead of print. Impactfactor: 7,2

Galan G, Long P, Cossio-Gil Y, Patalano F, Hamilton K, Huberts AS, Neureiter di Torrero A, Otto LR, Rogge AA, Fierens L, Lalji R, **de Rooij BH**, Porth AK, Watson CE, Kautzky-Willer A, Kamminga NC, Stamm T. A 10-step guide to standardising patient-reported outcomes data collection in healthcare: insights from the health outcomes observatory (H2O) project on overcoming implementation barriers. *J Patient Rep Outcomes*. 2025 Nov 28;9(1):138. doi: 10.1186/s41687-025-00958-2. Impactfactor: 2,9

Gueltzow M, **Bijlsma MJ**, van Lenthe FJ. Beyond associations: from theory to interventions in health inequalities research using causal inference. *Ann Epidemiol*. 2025 Oct 6:S1047-2797(25)00288-1. doi: 10.1016/j.annepidem.2025.10.001. Online ahead of print. Impactfactor: 3,0

**Heipon CS, Brom L**, van der Deure WM, Dingemans I, Geerse OP, Lauer S, de Vos FY, van der Linden YM, Reyners AK, **Raijmakers NJ**. Timely integration of palliative care into oncology in hospitals in the Netherlands: a feasibility study. *BMC Health Serv Res*. 2025 Sep 30;25(1):1231. doi: 10.1186/s12913-025-13199-2. Impactfactor: 3,0

**Heipon CS, Raijmakers NJ**, Dingemans I, Reyners AK, van der Linden YM, **Brom L**. Timely integration of palliative care into standard oncology care: an interview study with clinicians and patients with incurable cancer. *Palliat Support Care*. 2025 Jul 8;23:e129. doi: 10.1017/ S1478951525100333. Impactfactor: 2,8

Hemming L, **Duijts SF**, Cockburn C, Wilson C, Yuen EY, Spelten E. What do patients with a rare cancer living in rural, regional or remote areas and stakeholders want from a peer support program? a qualitative study. *BMC Cancer*. 2025 Feb 25;25(1):352. doi: 10.1186/s12885-025-13782-0. Impactfactor: 3,4

Hoffstädt HE, Klapwijk MS, **Hartog ID, van der Linden YM**, Mertens BJ, **Stoppelenburg A**, van der Steen JT. Supporting family caregivers of nursing home residents with dementia in their last week of life: a survey among bereaved family caregivers. *Palliat Med Rep*. 2025 Mar 5;6(1):105-115. doi: 10.1089/pmr.2024.0088. eCollection 2025. Impactfactor: 1.3

Holtmaat K, van Beek FE, Wijnhoven LM, Custers JA, Aukema EJ, Eerenstein SE, van Oort IM, Werner JE, Wegdam JA, Jansen-Engelen IL, de Hingh IH, Verheul S, van der Beek DT, Wekking G, Steggerda I, Coupé VM, **Horevoorts N, de Korte AM, Lammens C**, Lissenberg-Witte BI, **de Rooij BH**, Prins JB, Verdonck-de Leeuw IM, Jansen F. Efficacy and budget impact of a tailored psychological intervention program targeting cancer patients with adjustment disorder: a randomised controlled trial. *Psychooncology*. 2025 Mar;34(3):e70123. doi: 10.1002/pon.70123. Impactfactor: 3,5

**Hoveling LA, Eijkelboom A, Schuurman M**, Bode C, **Atema V**, van Laarhoven HW, Oertelt-Prigione S, **Richters A**, van Asselt KM, **Siesling S, Aarts MJ**. Disparities in cancer incidence and stage at diagnosis between male and female patients in the Netherlands. *Eur J Cancer*. 2025 Oct 20;230:116063. doi: 10.1016/j.ejca.2025.116063. Online ahead of print. Impactfactor: 7,1

Huberts AS, Long P, Porth AK, Fierens L, Carney NC, Koppert L, Kautzky-Willer A, **de Rooij BH**, Stamm T. Tracking chronic diseases via mobile health applications: which user experience aspects are key? *Healthcare (Basel)*. 2025 Dec 12;13(24):3272. doi: 10.3390/healthcare13243272. Impactfactor: 2,1

Janssen SH, van der Graaf WT, Hurley-Wallace A, **Vlooswijk C**, Padilla CS, Cairns C, Tyler CJ, Holthuis EI, Rohde GE, Hunt KJ, Way K, Angoumis K, Lankhorst LH, Engel MF, Rothmund MS, Reuvers MJ, Collaço N, Wagland R, Sodergren SC, Hanebaum S, Legendal T, Cartledge TJ, Bootsma TI, Bai Y, Darlington AS, Husson O. Core patient-centered outcomes for adolescents and young adults with cancer: a comprehensive review of the literature from the STRONG-AYA project. *Cancers (Basel)*. 2025 Jan 28;17(3):454. doi: 10.3390/cancers17030454. Impactfactor: 4,4

Janssen SH, **Vlooswijk C**, Bijlsma RM, Kaal SE, Kerst JM, Tromp JM, Bos ME, van der Hulle T, Lalisang RI, Nuver J, Kouwenhoven MC, van der Graaf WT, Husson O. Health-related quality of life of long-term adolescent and young adult (AYA) cancer survivors compared to a matched normative population: results of the SURVAYA study. *J Cancer Surviv*. 2025 Jun 17. doi: 10.1007/s11764-025-01818-0. Online ahead of print. Impactfactor: 2,9

Kapitan D, Heddema F, Dekker A, **Sieswerda M**, Verhoeff BJ, Berg M. Data interoperability in context: the importance of open-source implementations when choosing open standards. *J Med Internet Res*. 2025 Apr 15;27:e66616. doi: 10.2196/66616. Impactfactor: 6,0

Kenkhuis MF, **Vlooswijk C**, Janssen SH, Kaal SE, Tromp JM, Bos ME, van der Hulle T, Lalisang RI, Nuver J, Bijlsma RM, van der Graaf WT, Husson O, Buffart LM. Associations of adherence to the World Cancer Research Fund lifestyle recommendations with health-related quality of life and fatigue in Adolescent and Young Adult (AYA) cancer survivors: results from the SURVAYA study. *J Cancer Surviv*. 2025 Sep 8. doi: 10.1007/s11764-025-01891-5. Online ahead of print. Impactfactor: 2,9

Kenkhuis MF, Doorenbos M, Mast IH, Aaronson NK, van Beurden M, Bohus M, Courneya KS, Daley AJ, Galvão DA, Goedendorp MM, van Harten WH, Hayes SC, Hiensch AE, Irwin ML, Kersten MJ, Knoop H, May AM, McConnachie A, van Mechelen W, Mutrie N, Newton RU, Nollet F, Oldenburg HS, Schmidt ME, Schmitz KH, Schulz KH, Sonke GS, Steindorf K, Stuiver MM, Taaffe DR, Thorsen L, **Velthuis MJ**, Wiskemann J, Mesters I, Ulrich CM, van Vulpen JK, Custers JAE, Buffart LM. Exercise effects on symptoms of depression and anxiety vary by patient, clinical, and intervention characteristics in cancer survivors: results from pooled analyses of individual participant data of 26 RCTs. *Support Care Cancer*. 2025 Jul 1;33(7):647. doi: 10.1007/s00520-025-09646-9. Impactfactor: 3,0

Langhout SA, Hermans SJ, Smit AJ, **Berkx E**, Kurk SA, Schade KJ, **Posthuma EF**, **Visser O**, Cornelissen JJ, **Huijgens PC**, Versluis J, van der Wilt M, **Dinmohamed AG**. Real-time data in cancer registries: validation of an automated data extraction system. *iScience*. 2025 Jul 3;28(8):113056. doi: 10.1016/j.isci.2025.113056. eCollection 2025 Aug 15. Impactfactor: 4,1

Long P, Rogge A, Porth AK, Gross E, Fierens L, **de Rooij BH**, Kamminga N, Stamm T. Standardizing patient-reported outcomes across diseases: development of a novel generic patient-reported outcome set. *Front Health Serv*. 2025 Oct 2;5:1497055. doi: 10.3389/frhs.2025.1497055. eCollection 2025. Impactfactor: 2,7

**Maas CC**, Kent DM, **Dinmohamed AG**, van Klaveren D. Diverging conclusions from risk difference and difference in restricted mean survival time in quantifying absolute treatment effect heterogeneity. *Int J Epidemiol*. 2025 Oct 14;54(6):dyaf191. doi: 10.1093/ije/dyaf191. Impactfactor: 5,9

**Mols F**, van Willegen N, Lek D, Engelen V. The positive and negative impact of cancer on daily life > 2 years after diagnosis: results from a survey among 5,710 patients with various cancer types. *J Cancer Surviv*. 2025 Jul 17. doi: 10.1007/s11764-025-01870-w. Online ahead of print. Impactfactor: 2,9

**Oerlemans S**, Lodder P, van der Baan F, Giesinger JM, **Ezendam NP**. Development and validation of crosswalks between the EORTC QLQ-C30 physical, role, social and emotional functioning, fatigue and global health status/ quality of life scales and their corresponding PROMIS scales. *J Clin Epidemiol*. 2025 May 28:111853. doi: 10.1016/j.jclinepi.2025.111853. Online ahead of print. Impactfactor: 5,2

Pineda-Moncusí M, Rekkas A, Martínez Pérez Á, Leis A, Lopez Gomez C, Fey E, Bruninx E, Maljković F, Sánchez-Sáez F, Rodeiro-Boliart J, Zsuzsa Kiss L, Franz M, Mayer MA, Eleangovan N, Pulido PP, Natsiavas P, Şen S, Cooper S, Reisberg S, Manlik K, Price DB, Moschetti L, Merkelbach M, Tadrous M, Rappoport N, Claire R, Garcia-Torrens S, Prieto-Alhambra D, Rijnbeek PR, Burkard T; Drug Shortages EHDEN Study Group (**Evers J**, **Prinsen P**). Changes in use and utilisation patterns of drugs with reported shortages between 2010 and 2024 in Europe and North America: a network cohort study. *Lancet Public Health*. 2025 Oct;10(10):e835-e847. doi: 10.1016/S2468-2667(25)00194-X. Impactfactor: 25,2

Shuftan N, Dayan M, Scobie S, Wee B, Dimova A, Atanasova E, Murauskiene L, Gandré C, Or Z, Augusto GF, Habicht T, Köhler K, Kahur K, Axelsson B, Kroneman M, de Jong J, de Veer A, Bemelmans W, **Pereira C**, Aggarwal A, Davies J, van Ginneken E, Panteli D. The variation of coverage and access to palliative care for cancer patients in eight European countries: an exploratory vignette approach. *BMC Palliat Care*. 2025 Jul 7;24(1):188. doi: 10.1186/s12904-025-01831-1. Impactfactor: 3,0

Smissen DV, Lugtenberg M, Enting M, Beerepoot L, **Mols F**, Brouwers E, Wasowicz D, Joosen M. Getting back on track after treatment of cancer: a qualitative interview study of cancer survivors' experiences. *PLoS One*. 2025 Jan 9;20(1):e0313984. doi: 10.1371/journal.pone.0313984. eCollection 2025. Impactfactor: 2,6

Smits RM, Aerts A, Angelov T, Bentele M, de Blaauw I, Dellenmark-Blom M, **Duijts SF**, Fjermestad K, Franscini M, Grano C, Hendriks S, Inhestern L, Kenny T, von der Lippe C, Oomen L, Rake JP, Rietman

AB, van Rooij IA, Verhaak CM, Voet NB, Walton H, van Zelst-Stams W, Kwakkenbos L. Addressing psychosocial vulnerability in rare diseases: a call to action from a European expert consensus study. *Orphanet J Rare Dis.* 2025 Oct 27;20(1):543. doi: 10.1186/s13023-025-04017-3. Impactfactor: 3,5

**Sprengers R**, Monninkhof EM, Eijkelkamp N, van der Wall E, **Siesling S**, May AM, Hiensch AE. Systematic review and meta-analysis on the effect of physical exercise on self-reported pain in patients with metastatic cancer. *J Cancer Surviv.* 2025 Nov 14. doi: 10.1007/s11764-025-01936-9. Online ahead of print. Impactfactor: 2,9

Trama A, Rossi S, Bennet D, Stiller C, Paapsi K, Troussard X, Giudici F, **Karim-Kos HE**, Cerza F, Trallero J, Ragusa R, Blum M, Mayer-da-Silva A, Peters F, Didonè F, Botta L; EUROCARE-6 Working Group. Comparative analysis of 5-year relative survival in adolescents and young adults with cancer relative to both children and adults in Europe (EUROCARE-6): results from a population-based study. *Eur J Cancer.* 2025 Jun 11;226:115535. doi: 10.1016/j.ejca.2025.115535. Online ahead of print. Impactfactor: 7,1

Trama A, Rossi S, Bennet D, Stiller C, Paapsi K, Troussard X, Giudici F, **Karim-Kos HE**, Cerza F, Trallero J, Ragusa R, Blum M, Mayer-da-Silva A, Peters F, Didonè F, Botta L; EUROCARE-6 Working Group. Corrigendum to "Comparative analysis of 5-year relative survival in adolescents and young adults with cancer relative to both children and adults in Europe (EUROCARE-6): results from a population-based study" [*Eur. J. Cancer* 2025 Aug 26;226:115535. PMID: 40743655]. *Eur J Cancer.* 2025 Sep 12;229:115767. doi: 10.1016/j.ejca.2025.115767. Online ahead of print. Impactfactor: 7,1

**van de Graaf D**, van der Lee M, Smeets T, Trompetter H, **Mols F**. Exploring barriers and facilitators to engagement of an online acceptance and commitment therapy intervention for cancer survivors with chronic painful chemotherapy-induced peripheral neuropathy: qualitative interview study. *JMIR Cancer.* 2025 Sep 26;11:e64983. doi: 10.2196/64983. Impactfactor: 2,7

**van der Meer IS**, **Versluis MA**, **Fransen HP**, Eeltink CM, Baars A, Sommeijer DW, Smilde TJ, van der Padt-Pruijsten A, **van de Poll-Franse LV**, **Raijmakers NJ**. Sexual health at the end of life in patients with advanced cancer and their partners: results of a Dutch prospective longitudinal study (eQuiPe). *Palliat Med.* 2025 Nov 14;2692163251385774. doi: 10.1177/02692163251385774. Online ahead of print. Impactfactor: 3,9

**van der Ven RG**, Westra D, **van Erning FN**, **de Hingh IH**, Paulus A; OncoZON consortium. Going in circles?: Identifying the dissemination process of healthcare networks within their member organizations. *Soc Sci Med.* 2025 Jun 10;381:118311. doi: 10.1016/j.socscimed.2025.118311. Online ahead of print. Impactfactor: 5,0

**van der Ven RG**, Westra D, **van Erning FN**, **de Hingh IH**, Paulus A; OncoZON consortium. Organizing contemporary oncology care together: a scoping review on multi-hospital oncology networks. *J Cancer Policy.* 2025 Oct 16;46:100651. doi: 10.1016/j.jcpo.2025.100651. Online ahead of print. Impactfactor: 2,0

**van Deursen L**, **de Korte AM**, van der Vaart R, Aardoom JJ, **Stouten MM**, **Lammens CR**, Chavannes NH, Struijs JN. Investigating the early uptake of digital self-management interventions amongst Dutch cancer survivors using nationwide registry data: the OncoAppstore case. *Support Care Cancer.* 2025 Oct 17;33(11):964. doi: 10.1007/s00520-025-10035-5. Impactfactor: 3,0

van Geffen LP, **Mols F**, Geurts VC, Vreugdenhil G. Carnitine levels decrease during oxaliplatin infusion: a pilot study. *Chemotherapy.* 2025;70(3):153-162. doi: 10.1159/000546614. Epub 2025 May 24. Impactfactor: 1,7

**van Velzen N**, **Brom L**, van der Vorst MJ, Kiers ML, Wagemans MF, Kazimier H, **Boddaert MS**, **Raijmakers NJ**, Stoppelenburg A. Development of specialist palliative care in Dutch hospitals between

2014 and 2020: a repeated survey. *BMC Palliat Care*. 2025 Jan 23;24(1):20. doi: 10.1186/s12904-025-01657-x.

Impactfactor: 3,0

**Versluis MA**, de Boer EC, **van de Poll-Franse LV**, **Raijmakers NJ**, **Vissers PA**, Dingemans IH, de Ruiter MB, Slingerland M, Reyners AK, Tesselaar ME, Wymenga AN. Differences in travel burden between patients with self-reported curable and incurable cancer: results from a Dutch flash mob study. *Support Care Cancer*. 2025 Jun 23;33(7):610. doi: 10.1007/s00520-025-09675-4.

Impactfactor: 3,0

**Versluis MA**, **van der Linden YM**, **Oerlemans S**, Sommeijer DW, de Jong WK, Baars A, Smilde TJ, van der Padt-Pruijsten A, **van de Poll-Franse LV**, **Raijmakers NJ**. Socioeconomic disparities in health-related quality of life and healthcare use in the last year of life of patients with advanced cancer: longitudinal results from the eQuiPe study. *Support Care Cancer*. 2025 Mar 11;33(4):265. doi: 10.1007/s00520-025-09309-9.

Impactfactor: 3,0

**Vlooswijk C**, Sleeman SH, Pluis J, Bakker D, de Groot L, Manten E, Heine P, Husson O, **van Eenbergen MC**, Vandekerckhove P. Developing and integrating digital sources in an accessible and sustainable online platform for adolescents and young adult cancer survivors: collaborative design approach. *JMIR Form Res*. 2025 Jul 11;9:e60897. doi: 10.2196/60897.

Impactfactor: 2,1

Vrancken Peeters NJ, van der Meer DJ, Wardenier B, L'hôte M, Manten-Horst E, **Karim-Kos HE**, van der Graaf WT, Husson O. 5-Year conditional relative survival of adolescents and young adults with solid malignancies in the Netherlands: a population-based cohort study. *Lancet Reg Health Eur*. 2025 Aug 13;57:101429. doi: 10.1016/j.lanepe.2025.101429. eCollection 2025 Oct.

Impactfactor: 13,0

Zegers AD, Motazed E, **de Heus E**, **Ho V**, Coenen P, Tamminga SJ, **Duijts SF**. Comparing loss of contractual employment pre- and post-diagnosis in patients with rare versus common cancer types: a national registry-based study. *J Cancer Surviv*. 2025 Jan 6. doi: 10.1007/s11764-024-01726-9. Online ahead of print.

Impactfactor: 2,9

## 1.2 Overige publicaties

de Haan-Du J, Groenier KH, Kleefstra N, van der Vegt B, **Siesling S**, Landman GW, de Bock GH. Socioeconomic disparity in stage at cancer diagnosis among patients with type 2 diabetes in Dutch primary care: a cross-sectional study. *BMJ Public Health*. 2024 Mar 14;2(1):e000050. doi: 10.1136/bmjph-2023-000050. eCollection 2024 Jun.

**Pasman R**, **Jacobs FJ**, Eshuis R, de Kroon CD, **Sloep M**, **van der Werf J**, **Ebben KC**. Integrating real-world data and computational guidelines: designing a dashboard for nationwide evaluation of molecular diagnostics in oncology. *Stud Health Technol Inform*. 2025 May 15;327:1393-1397. doi: 10.3233/SHTI250631.

**van Son D**, **Versluis MA**, **van de Poll-Franse LV**, **Raijmakers NJ**. Kwaliteit van zorg en leven bij uitgezaaide kanker en hun naasten: inzichten uit de eQuiPe-studie. *NtvG* 169(2025)2(feb); 37-41.

**van Vegchel T**, **Ebben KC**. Using data-driven decision algorithms and real-world data for updating clinical practice guidelines. *Stud Health Technol Inform*. 2025 May 15;327:229-230. doi: 10.3233/SHTI250312.

## 1.3 Proefschriften en promoties

**Heipon CS**. Timely integration of palliative care into oncology. Groningen: Rijksuniversiteit; 12 juni 2025. Promotoren: AK Reyners, **YM van der Linden**. Copromotoren: **NJ Raijmakers**, **L Brom**.

Hoogendijk R. Epidemiology of pediatric central nervous system tumors: back to the future. Utrecht: Universiteit; 2 april 2025. Promotoren: EW Hoving, P Wesseling. Copromotoren: **HE Karim-Kos**, DG van Vuurden.

---

**Maas CC.** Methods for prediction in cancer. Rotterdam: Erasmus Universiteit; 23 april 2025. Promotor: H Lingsma, VE Lemmens, van Klaveren D, **AG Dinmohamed**.

**Schuurman MS.** Contrasting cancer landscapes: older versus younger adults. Rotterdam: Erasmus Universiteit; 19 december 2025. Promotor: VE Lemmens. Copromotor: **MA van der Aa**.

**Sieswerda MS.** Reusing routine cancer data for registries and decision support. Maastricht: Universiteit; 4 april 2025. Promotoren: AL Dekker, VE Lemmens.

Vazifehdostirani M. Leveraging process flexibility to improve process outcome: from descriptive analysis to actionable insights. Eindhoven: Technische Universiteit; 23 september 2025. Promotor: RM Dijkman  
Copromotoren: L Genga, **RH Verhoeven**.

**Vlooswijk C.** Improving (Digital) care for adolescent and young adult cancer survivors: insights from patient-reported outcomes. Rotterdam: Erasmus Universiteit; 15 oktober 2025. Promotoren: WT van der Graaf, LV van de Poll-Franse, O Husson.

**Vrinzen C.** Sustainable cancer care: enhancing value and managing costs. Nijmegen: Radboud Universiteit; 25 april 2025. Promotoren: PP Jeurissen, HJ Bloemendal, **MA Merkx**, RP Hermens.  
Manuscriptcommissie: M Verheij, JJ Polder, **S Siesling**.

## 2 Borstkanker

### 2.1 Publicaties met impactfactor

Bakhuis CF, Preković S, Suelmann BB, [Verloop J](#), Westenend PJ, Linn SC, van Diest PJ, van der Wall E, van Dooijeweert C. *Worse prognosis for breast cancer diagnosed in advanced pregnancy and shortly postpartum: an update of the Dutch pregnancy-associated breast cancer cohort*. *Breast Cancer Res Treat*. 2025 Aug 12. doi: 10.1007/s10549-025-07806-3. Online ahead of print. Impactfactor: 3,0

Beenhakker L, Wijlens KA, Bode C, Vollenbroek-Hutten MM, [Siesling S](#), van Til JA, Witteveen A. *Working toward personalized intervention advice: a survey study on preference heterogeneity in patients with breast cancer-related fatigue*. *MDM Policy Pract*. 2025 Jan 13;10(1): 23814683241309676. doi: 10.1177/23814683241309676. eCollection 2025 Jan-Jun. Impactfactor: 1,7

Beltran-Bless AA, Saunders D, Clemons L, Machado I, Pond G, Hutton B, El-Emam K, McGee S, Ng TL, Savard MF, Hilton J, Rushton M, Larocque G, [Siesling S](#), Leblanc A, Vandermeer L, Clemons M. *Patient perceptions around the use of clinico-pathologic and genomic tools in the management of early breast cancer*. *Breast Cancer Res Treat*. 2025 Aug 21. doi: 10.1007/s10549-025-07797-1. Online ahead of print. Impactfactor: 3,0

Civil YA, [Eijkelboom AH](#), [Veldink AE](#), van Maarenc MC, Maduro JH, Duvivier KM, [Siesling S](#), van den Bongard HJ. *Trends in use of magnetic resonance imaging and partial breast irradiation between 2011-2022 in the Netherlands: a population-based study*. *Clin Transl Radiat Oncol*. 2025 Aug 31;55:101039. doi: 10.1016/j.ctro.2025.101039. eCollection 2025 Nov. Impactfactor: 2,7

Claassens EL, Ploumen RA, Kooreman LF, van Kats MA, [Siesling S](#), van Nijnatten TJ, Smidt ML. *The effect of neoadjuvant chemotherapy on ductal carcinoma in situ in triple-negative breast cancer patients: a nationwide analysis*. *Breast*. 2025 Feb 18;80:104425. doi: 10.1016/j.breast.2025.104425. Online ahead of print. Impactfactor: 7,9

de Graaf M, Gielen RC, Balduzzi S, [Siesling S](#), Linn SC, Kok M. *Pathological complete response and survival after neoadjuvant chemotherapy in patients with stage I TNBC: a registry-based study*. *ESMO Open*. 2025 Dec 5;10(12):105923. doi: 10.1016/j.esmoop.2025.105923. Online ahead of print. Impactfactor: 8,3

[Dekker-Klaassen A](#), Drossaert CH, Thé R, Zeillemaker AM, van Hezewijk M, De Keulenaar-Suiker IM, Knottnerus BJ, Honkoop A, van der Lee ML, Korevaar JC, [Siesling S](#), on behalf of the Nabor Project Group. *A goal without a plan is just a wish: creating a personalized aftercare plan for breast cancer patients supported by the Breast Cancer Aftercare Decision Aid*. *Curr Oncol*. 2025 Oct 1;32(10):552. doi: 10.3390/currenco132100552. Impactfactor: 3,4

[Dekker-Klaassen A](#), Drossaert CH, Folkert LS, Van der Lee ML, Guerrero-Paez C, Claassen S, Korevaar JC, [Siesling S](#); NABOR project group. *Different needs ask for different care: breast cancer patients' preferences regarding assessment of care needs and information provision in personalized aftercare*. *Eur J Oncol Nurs*. 2025 Mar 18;76:102873. doi: 10.1016/j.ejon.2025.102873. Online ahead of print. Impactfactor: 2,7

Ding N, Hermans KE, van Nijnatten TJ, Engelen SM, Tol J, Kooreman L, Vrancken-Peeters MT, [Siesling S](#), Voogd AC, Tjan-Heijnen VC, Geurts SM. *Overall survival of patients with de Novo HER2-positive metastatic breast cancer in the Netherlands from 2008 to 2017: a population-based cohort study of systemically treated patients*. *Eur J Cancer*. 2025 Apr 26;222:115475. doi: 10.1016/j.ejca.2025.115475. Online ahead of print. Impactfactor: 7,1

**Eijkelboom AH**, van Beek EJ, Stam MR, Westhoff P, **van Maaren MC**, Sattler MG, Bantema-Joppe EJ, **Verheij M**, van den Bongard DH, **Siesling S**; NABON-COVID-19 Consortium and the COVID and Cancer-NL Consortium (**Verloop J**). Implementation of ultra-hypofractionated radiotherapy for breast cancer in the Netherlands in 2020-2023, using registry data and questionnaires. *Radiat Oncol*. 2025 Jun 12;20(1):99. doi: 10.1186/s13014-025-02669-w. Impactfactor: 3,2

**Godding LT**, **Dekker-Klaassen A**, Volders JH, van Hezewijk M, Siemerink EJ, van Uden D, Veltman J, **Eijkelboom AH**, **Siesling S**. The added value of physical examination for breast cancer recurrence detection in women: a systematic review. *Clin Breast Cancer*. 2025 Jan 11:S1526-8209(24)00365-3. doi: 10.1016/j.clbc.2024.12.014. Online ahead of print. Impactfactor: 2,5

Hoedjes M, van Cappellen-van Maldegem S, Nimtz C, van Loenen-Sarukhanyan Z, **van de Poll-Franse LV**, Seidell JC, **Mols F**. Maintenance of lifestyle changes following lifestyle interventions in breast cancer survivors: a systematic literature review. *Health Psychol Rev*. 2025 Aug 5:1-40. doi: 10.1080/17437199.2025.2539202. Online ahead of print. Impactfactor: 9,7

Hoveling LA, **Schuurman M**, **Siesling S**, van Asselt KM, Bode C. Diagnostic delay in women with cancer: what do we know and which factors contribute? *Breast*. 2025 Feb 19;80:104427. doi: 10.1016/j.breast.2025.104427. Online ahead of print. Impactfactor: 7,9

Hoveling LA, Heuken LP, Harfst T, **Schuurman MS**, van Asselt KM, **Siesling S**, Bode C. Understanding delays in breast cancer diagnosis in Africa: key insights and contributing factors. *Int J Cancer*. 2025 Jun 20. doi: 10.1002/ijc.70008. Online ahead of print. Impactfactor: 4,7

Jansen BA, Bargon CA, Bouman MA, van der Molen DR, Postma EL, van der Leij F, Zonneville E, Ruhe Q, Bruekers SE, Maarse W, **Siesling S**, Young-Afat DA, Doeksen A, Verkooijen HM; UMBRELLA study group. Patient-reported outcomes after immediate and delayed DIEP-flap breast reconstruction in the setting of post-mastectomy radiation therapy-results of the multicenter UMBRELLA breast cancer cohort. *Breast Cancer Res Treat*. 2025 Feb 3. doi: 10.1007/s10549-025-07613-w. Online ahead of print. Impactfactor: 3,0

Jansen BA, Kelder JC, Borchert T, van Uden DJ, van der Leij F, Schröder C, Doeksen A, **Siesling S**, **van Maaren MC**, Postma EL. Trends in surgical treatment for cT4 breast cancer after neoadjuvant systemic therapy: a nationwide study in the Netherlands. *Ann Surg Oncol*. 2025 Jun 18. doi: 10.1245/s10434-025-17585-2. Online ahead of print. Impactfactor: 3,5

Jilderda MF, Zhang Y, Rebattu V, Salunga R, Mesker W, Wong J, **de Munck L**, Fornander T, Nordenskjöld B, Stål O, Anderson AL, Bastiaannet E, Treuner K, Liefers G. Identification of early-stage breast cancer with minimal risk of recurrence by breast cancer index. *Clin Cancer Res*. 2025 Mar 27. doi: 10.1158/1078-0432.CCR-24-3836. Online ahead of print. Impactfactor: 10,2

Jilderda MF, Bartlett JM, Liefers GJ, Zhang Y, Dunn-Davies H, Rebattu V, Salunga R, Meershoek-Klein Kranenburg E, **de Munck L**, Hasenburg A, Markopoulos C, Dirix L, van de Velde CJ, Rea D, Anderson AK, Bastiaannet E, Treuner K, Taylor KJ. Validation of minimal risk of recurrence classification by the Breast Cancer Index in early stage breast cancer. *NPJ Breast Cancer*. 2025 Dec 30. doi: 10.1038/s41523-025-00885-x. Online ahead of print. Impactfactor: 7,6

Jong CL, **Siesling S**, **Puts GC**, Jager A, Ausems MG. The impact of a mainstream genetic testing pathway and socioeconomic factors on the uptake of germline genetic testing in breast cancer patients: results of the nationwide GENE-SMART study. *Breast Cancer Res*. 2025 Jul 14;27(1):129. doi: 10.1186/s13058-025-02081-y. Impactfactor: 5,6

Koevoets EW, Schagen SB, May AM, Geerlings MI, Witlox L, van der Wall E, Stuijver MM, Sonke GS, **Velthuis MJ**, Jobsen JJ, van der Palen J, de Ruiter MB, Monninkhof EM. Effect of physical exercise on white matter microstructure in chemotherapy-treated breast cancer patients: a randomized controlled trial (PAM study). *Brain Imaging Behav.* 2025 Jan 13. doi: 10.1007/s11682-024-00965-9. Online ahead of print. Impactfactor: 2,4

Lammers SW, Geurts SM, Hermans KE, Kooreman LF, **Swinkels AC**, Smorenburg CH, van der Sangen MJ, Kroep JR, Honkoop AH, van den Berkortel FW, de Roos WK, Linn SC, Imholz AL, Vriens IJ, Tjan-Heijnen VC; Dutch Breast Cancer Research Group (BOOG) for the DATA investigators. The prognostic and predictive value of the luminal-like subtype in hormone receptor-positive breast cancer: an analysis of the DATA trial. *ESMO Open.* 2025 Feb 7;10(2):104154. doi: 10.1016/j.esmoop.2025.104154. Online ahead of print. Impactfactor: 8,3

Meurs CJ, Kerkhoven C, **Siesling S**, Menke-Pluijmers MB, Westenend PJ. ASO Visual Abstract: Surgery for classic, pleomorphic and nonclassic lobular carcinoma in situ surgery rate, risk of upstaging and short-term follow-up. *Ann Surg Oncol.* 2025 Feb 4. doi: 10.1245/s10434-025-16906-9. Online ahead of print. Impactfactor: 3,5

**Meijer J**, van den Bongard HJ, Koppert LB, Menke-van der Houven van Oordt CW, **de Munck L**, van Nijnatten TJ, van der Sangen MJ, Schipper RJ, Schmidt MK, Smidt ML, Vreuls W, **van Maaren MC**, **Siesling S**. Trends in local, regional and contralateral breast tumor recurrence within five years after diagnosis in the Netherlands: a population-based study including 121347 patients. *Breast.* 2025 Dec 9;85:104673. doi: 10.1016/j.breast.2025.104673. Online ahead of print. Impactfactor: 7,9

Mink van der Molen DR, Batenburg MC, van 't Westeinde T, Houweling AC, Maarse W, Verhoeven K, Strijbos J, Murrer L, **Siesling S**, Monninkhof EM, Verkooijen HM, Boersma LJ, van der Leij F; UMBRELLA study group. Acute toxicity and quality of life after 5-fraction versus 15-fraction adjuvant radiotherapy following conventional or oncoplastic breast-conserving surgery: a real-world prospective cohort study. *Radiother Oncol.* 2025 Nov 30;214:111310. doi: 10.1016/j.radonc.2025.111310. Online ahead of print. Impactfactor: 5,3

Potter S, Avery K, Ahmed R, de Boniface J, Chatterjee S, Dodwell D, Dubsky P, Federmann J, Finestone S, Gnani M, Hlouschek D, Iwata H, Jiang MY, Kaidar-Person O, Lee HB, MacKenzie M, Meyn A, Poortmans P, Poulakaki F, Richardson AL, Sepulveda KA, Spillane AJ, Thompson AM, Werutsky G, Wittmann P, Wright JL, Zdenkowski N, Cowan K, McIntosh SA; PRECEDENT Study Group (**van Maaren MC**). A core outcome set for locoregional treatment reporting in neoadjuvant systemic breast cancer treatment trials. *NPJ Breast Cancer.* 2025 Oct 28;11(1):116. doi: 10.1038/s41523-025-00824-w. Impactfactor: 7,6

Schreurs MA, Adank MA, Heemskerk-Gerritsen BA, Hollestelle A, Smallenbroek N, van Asperen CJ, Ausems MG, van de Beek I, de Bock GH, Boere I, van Hest LP, van Kaam KJ, **de Munck L**, Vos JR, Jager A, Schmidt MK, Hooning MJ; Hebon. Outcomes for ER-positive CHEK2 c.1100delC breast cancer patients compared with breast cancer patients without the variant. *Breast.* 2025 Nov 24;85:104666. doi: 10.1016/j.breast.2025.104666. Online ahead of print. Impactfactor: 7,9

Sonke GS, van Ommen-Nijhof A, Wortelboer N, van der Noort V, **Swinkels AC**, Blommestein HM, Guerrero Paez C, **Mol L**, Beeker A, Beelen K, Hamming LC, Heijns JB, Honkoop AH, de Jong PC, van Rossum-Schornagel QC, van Schaik-van de Mheen C, Tol J, Tromp-van Driel CS, Vrijaldenhoven S, van Leeuwen-Stok AE, Konings IR, Jager A; SONIA Study Consortium. Author Correction: Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer. *Nature.* 2025 Jul 22. doi: 10.1038/s41586-025-09406-z. Online ahead of print. Impactfactor: 48,5

Stroot IA, Bart J, Hollema H, Wagner MM, Yigit R, van Doorn HC, de Hullu JA, Gaarenstroom KN, van Beurden M, van Lonkhuijzen LR, Slangen BF, Zweemer RP, Gómez Garcia EB, Ausems MG, Komdeur FL, van Asperen CJ, Adank MA, Wevers MR, Hooning MJ; HEBON Investigators (**Siesling S**, **Verloop J**); Mourits MJ, de Bock GH. High-grade serous carcinoma occurring after risk-reducing salpingo-

oophorectomy in BRCA1/2 germline pathogenic variant carriers. *J Natl Cancer Inst.* 2025 Apr 1;117(4):719-727. doi: 10.1093/jnci/djae300.  
Impactfactor: 7,2

Tamminga SJ, de Wind A, Greidanus MA, Coenen P, Friberg E, Oldenburg HS, **Duijts SF**, de Boer AG. **Prognostic factors for return to work in breast cancer survivors.** *Cochrane Database Syst Rev.* 2025 May 7;5:CD015124. doi: 10.1002/14651858.CD015124.pub2.  
Impactfactor: 9,4

van Amstel FJ, van Mierlo RG, Nelemans PJ, Engelen SM, Houwers J, Kooreman LF, Tjan-Heijnen VC, **Siesling S**, Smidt ML, van Nijnatten TJ. **Primary tumour response on breast MRI as a predictor of axillary pathologic response in breast cancer patients treated with neoadjuvant chemotherapy.** *Eur Radiol.* 2025 Dec 23. doi: 10.1007/s00330-025-12249-x. Online ahead of print.  
Impactfactor: 4,7

van Cappellen-van Maldegem SJ, Kruif A, Seidell JC, **van de Poll-Franse LV**, **Mols F**, Hoedjes M. **Determinants and timing of lifestyle changes in postmenopausal breast cancer survivors: a longitudinal qualitative study.** *PLoS One.* 2025 Nov 24;20(11):e0337089. doi: 10.1371/journal.pone.0337089.  
eCollection 2025.  
Impactfactor: 2,6

van der Linden BW, Carmeli C, **Duijts SF**, Guseva Canu I, Rohrmann S, Chiolero A. **The impact of working conditions on breast cancer outcomes: a study protocol for a population-based cohort study using UK Biobank data.** *BMJ Open.* 2025 Sep 30;15(9):e108615. doi: 10.1136/bmjopen-2025-108615.  
Impactfactor: 2,3

van Hage P, le Cessie S, **van Maaren MC**, Putter H, van Geloven N. **Doubly robust estimation of marginal cumulative incidence curves for competing risk analysis.** *Stat Med.* 2025 Aug;44(18-19):e70066. doi: 10.1002/sim.70066.  
Impactfactor: 1,8

**van Maaren MC**, Voorham QJ, **Wijnen EM**, **de Munck L**, Wesseling J, **Visser O**, **Siesling S**. **Notification of locoregional breast cancer recurrence based on pathology reports: a nationwide validation study with the Netherlands Cancer Registry.** *Cancer Epidemiol.* 2025 Mar 5;96:102780. doi: 10.1016/j.canep.2025.102780. Online ahead of print.  
Impactfactor: 2,3

van Winkel SL, Peters J, Janssen N, Kroes J, Loehrer EA, Gommers J, Sechopoulos I, **de Munck L**, Teuwen J, Broeders M, Karssemeijer N, Mann RM. **AI as an independent second reader in detection of clinically relevant breast cancers within a population-based screening programme in the Netherlands: a retrospective cohort study.** *Lancet Digit Health.* 2025 Jul 23:100882. doi: 10.1016/j.landig.2025.100882. Online ahead of print.  
Impactfactor: 24,1

Verreck EE, Postma EL, Oostergo T, **Meijer J**, **Eijkelboom A**, **Siesling S**, Rizopoulos D, van Dalen T, Volders JH. **Less endocrine therapy in HR+/HER2- breast cancer: a nationwide trend despite unchanged guidelines.** *Breast.* 2025 Nov 26;85:104664. doi: 10.1016/j.breast.2025.104664. Online ahead of print.  
Impactfactor: 7,9

Vrancken Peeters NJ, van der Meer DJ, Kok M, **van Maaren MC**, Peeters MT, **Siesling S**, van der Graaf WT, Husson O. **Five-year conditional relative survival up to 10 years post-diagnosis among adolescent and young adult breast cancer patients by age, stage, and receptor subtype.** *J Natl Cancer Cent.* 2025 Mar 31;5(3):297-305. doi: 10.1016/j.jncc.2025.01.005. eCollection 2025 Jun.  
Impactfactor: 9,4

Vrancken Peeters NJ, Kerklaan R, **Vlooswijk C**, Bijlsma RM, Kaal SE, Tromp JM, Bos ME, van der Hulle T, de Boer M, Nuver J, Kouwenhoven MC, van der Graaf WT, Husson O. **Long-term health-related quality of life among adolescent and young adult breast cancer survivors.** *Qual Life Res.* 2025 Feb 21. doi: 10.1007/s11136-025-03914-1. Online ahead of print.  
Impactfactor: 2,7

Vreven LW, Verheul EM, [van Maaren MC](#), Doornkamp F, Schipper RJ, [Siesling S](#), Pharoah PD, Tjan-Heijnen VC, Voogd AC. Comparative validation of PREDICT versions 3.1 and 2.2 for overall survival in the Dutch breast cancer population. *Breast*. 2025 Dec 16;85:104681. doi: 10.1016/j.breast.2025.104681. Online ahead of print. Impactfactor: 7,9

Westenend PJ, Meurs CJ, [Siesling S](#), Menke-Pluijmers MB. ASO Author Reflections: sentinel lymph node biopsy for patients with a non-classic lobular carcinoma In situ breast biopsy. *Ann Surg Oncol*. 2025 Jan 17. doi: 10.1245/s10434-024-16863-9. Online ahead of print. Impactfactor:3,5

Wortelboer N, Kent S, Konings IR, van Ommen-Nijhof A, van der Noort V, [van den Pol E](#), Guerrero Páez C, van Bekkum ML, van den Berkmortel FW, Droogendijk HJ, Houtsma D, Oosterkamp HM, van der Padt-Pruijsten A, Siemerink EJ, Tol J, van Zweeden AA, van Leeuwen-Stok AE, Sonke GS, Jager A, Blommestein HM. Health economic outcomes and costs of CDK4/6 inhibitor use in first- versus second-line for advanced breast cancer: a cost-effectiveness analysis of the phase 3 SONIA trial. *Eur J Cancer*. 2025 Oct 25;231:116051. doi: 10.1016/j.ejca.2025.116051. Online ahead of print. Impactfactor: 7,1

Wortelboer N, Kent S, Blommestein HM, van Ommen-Nijhof A, van der Noort V, [van den Pol E](#), Páez CG, Beeker A, Beelen K, Hamming LC, Heijns JB, Honkoop AH, de Jong PC, van Rossum-Schornagel QC, van de Mheen CV, Tol J, Driel CS, Vrijaldenhoven S, van Leeuwen-Stok AE, Sonke GS, Jager A, Konings IR. Health-related quality of life with first- vs second-line CDK4/6 inhibitor use in advanced breast cancer: results from the SONIA trial. *J Natl Cancer Inst*. 2025 Nov 21:djaf334. doi: 10.1093/jnci/djaf334. Online ahead of print. Impactfactor: 7,2

## 2.2 Overige publicaties

[Dekker-Klaassen A](#), Godding LT, van Hezewijk M, Korevaar JC, Wieggersma J, Drossaert CH, [Siesling S](#); on behalf of the NABOR project group. Perspectives of health care professionals on the value of physical examination for early detection of breast cancer recurrences: more than just a detection method? *Measurement and evaluations in cancer care* 2025 3;100016.

## 2.3 Proefschriften en promoties

Herijgers-Beenhakker I. *Breast cancer-related fatigue risk and intervention recommendations: what can and cannot be personalized?* Enschede: Universiteit Twente; 16 oktober 2025. Promotor: MM Vollenbroek-Hutten, [SSiesling](#), A Witteveen.

[Luyendijk M](#). *Making cancer data meaningful: using real-world data to evaluate cancer care and outcomes, and support evidence-based decision-making*. Rotterdam: Erasmus Universiteit; 21 november 2025. Promotoren: C de Groot, [SSiesling](#), A Jager. Copromotor: H Blommestein.

Ploumen RA. *Sustainable cancer care: enhancing value and managing costs*. Maastricht: Universiteit; 14 april 2025. Promotor: ML Smidt. Copromotoren: TJ van Nijntzen, [SSiesling](#).

Voets MM. *From promise to practice: evaluating the health and economic impact of AI in breast cancer imaging surveillance*. Enschede: Universiteit Twente; 25 november 2025. Promotoren: [S Siesling](#), E Koffijberg.

---

## 3 Bot-en wekedelentumoren

### 3.1 Publicaties met impactfactor

van Oss A, [Stoppelenburg A](#), de Nijs E, van Jaarsveld R, [Heipon CS](#), [Raijmakers NJ](#), [van der Linden YM](#). Timely integration of palliative care into oncology care for patients with bone metastases at the radiotherapy department: a pilot study on acceptability and feasibility. *Tech Innov Patient Support Radiat Oncol.* 2025 Jun 10;35:100317. doi: 10.1016/j.tipsro.2025.100317. eCollection 2025 Sep.  
Impactfactor: 2,8

## 4 Darmkanker

### 4.1 Publicaties met impactfactor

Boute TC, van Eekelen R, **Elferink MA**, Lissenberg-Witte B, de Wilt JH, **Vink GR**, Greuter MJ, Coupé VM. Follow-up adherence after treatment with curative intent for stage II and III colorectal cancer patients. *Cancer Med.* 2025 Mar;14(5):e70667. doi: 10.1002/cam4.70667. Impactfactor: 3,1

**Bruijnzeels AE, Mols F**, Van Deun K, **Schoormans D**. Effects of cancer treatment on inflammation in colorectal cancer patients: a longitudinal study. *Clin Colorectal Cancer.* 2025 Dec 13:S1533-0028(25)00108-2. doi: 10.1016/j.clcc.2025.12.001. Online ahead of print. Impactfactor: 3,2

Darai A, Koëter T, **van Erning FN**, van Alphen RJ, Verheul HM, Verheij M, Zimmerman DD, **Vissers PA**, de Wilt JH. The role of adjuvant chemotherapy in rectal cancer: a nationwide cohort study from the Netherlands. *Colorectal Dis.* 2025 Mar;27(3):e70054. doi: 10.1111/codi.70054. Impactfactor: 2,7

Darai A, de Vries S, Beets GL, Nagtegaal ID, Couwenberg AC, Moons LM, **van Erning FN, Vissers PA**, de Wilt JH, Grotenhuis BA. Trends in organ preservation in rectal cancer management: a population-based study in the Netherlands. *Eur J Cancer.* 2025 Nov 29;232:116154. doi: 10.1016/j.ejca.2025.116154. Online ahead of print. Impactfactor: 7,1

de Graaff MR, Klaase JM, den Dulk M, Grünhagen DJ, Swijnenburg RJ, Kazemier G, Liem M, Belt EJ, Vermaas M, Mieog JS, Gobardhan P, Rijken A, Oosterling SJ, Bosscha K, Kok NF, **Elferink MG**; Dutch Hepato Biliary Audit Group (DHBA) and National Cancer Registry (NCR). Selection for local treatment and outcomes of surgical resection in patients with synchronous colorectal liver metastases: a nationwide population-based study. *Eur J Surg Oncol.* 2025 Aug 28;51(11):110411. doi: 10.1016/j.ejso.2025.110411. Online ahead of print. Impactfactor: 2,9

de Nes LC, Tanis PJ, **Verhoeven RH**, de Wilt JH, **Vissers PA**. Impact of hospital volume on survival in patients with locally advanced colon cancer: a Dutch population-based study. *Colorectal Dis.* 2025 Feb;27(2):e17288. doi: 10.1111/codi.17288. Impactfactor: 2,7

de Vries-ten Have J, Winkens LH, Verkaar AJ, Bloemhof SA, Schepers L, Manusama K, **Beijer S**, Sommeijer DW, van Eekeren RR, Kruyt F, Guitink A, Kampman E, Winkels RM. The effect of a person-centred lifestyle program on cancer-related fatigue in colorectal cancer survivors: a randomized trial. *Br J Nutr.* 2025 Dec 9:1-32. doi: 10.1017/S0007114525105862. Online ahead of print. Impactfactor: 3,0

Franken IA, van der Baan FH, Roodhart JM, Koopman M, **Vink GR**, May AM, van Grevenstein WM. Reply to: Putting IDEA's results into practice: practicality should rule complexity in stage III colon cancer. *JCO Oncol Pract.* 2025 Apr 17:OP2500130. doi: 10.1200/OP-25-00130. Online ahead of print. Impactfactor: 4,7

**Galanos LJ**, Rijken A, **Elferink MA**, Kok NF, **van Erning FN, De Hingh IH**. Influence of a nationwide colorectal cancer screening program on the incidence of synchronous colorectal peritoneal metastases. *Int J Cancer.* 2025 Feb 17. doi: 10.1002/ijc.35356. Online ahead of print. Impactfactor: 4,7

Hanevelt J, **van Erning FN**, de Vos Tot Nederveen Cappel WH, Vleggaar FP, van Westreenen HL, Moons LM. Trends over time and inter-hospital variation in the primary treatment approach for T1 colon carcinomas in the Netherlands. *Endoscopy.* 2025 Apr 27. doi: 10.1055/a-2595-5381. Online ahead of print. Impactfactor: 12,8

Kastelein A, **Mols F**, Kervezee L, Chavannes NH, Gelderblom H, Neeftjes J, Hinnen C. The impact of chemotherapy and body mass index on cancer-related fatigue in colon cancer patients: a PROFILES-registry study. *Cancer Med*. 2025 Jan;14(1):e70536. doi: 10.1002/cam4.70536. Impactfactor: 3,1

Kim H, **Shen L**, Jeon J, Han YD, Han DH, Jung M, Shin SJ, You SC, Kim NK, Min BS, Hur H, Ahn JB, Shin SJ, van Gestel AJ, **van Erning FN, Geleijnse G**, Kim HS. Number of lymph nodes examined as a prognosis factor in patients with stage II or III colon cancer. *Clin Colorectal Cancer*. 2025 Feb 28:S1533-0028(25)00025-8. doi: 10.1016/j.clcc.2025.02.004. Online ahead of print. Impactfactor: 3,2

Linssen JD, Schafrat PJ, de Back TR, **van Erning FN**, van Leerdam ME, Dekker E, Vermeulen L, **de Hingh IH**, Sommeijer DW. Predisposing conditions in patients with small intestinal adenocarcinomas in the Netherlands: a 20-year nationwide cohort study. *Int J Cancer*. 2025 Feb 5. doi: 10.1002/ijc.35354. Online ahead of print. Impactfactor: 4,7

Lunenberg RA, Franken IA, van der Baan FH, **Sijtsma FP, Vink GR**, Braat MN, Moons LM, Lacle MM, **Elferink MA**, Boklage S, Intven MP, Garside J, Koopman M, van Wuijtswinkel R, Roodhart JM. A comparison by mismatch repair status of real-world characteristics and outcomes in patients with stage II/III rectal cancer in the Netherlands. *Int J Cancer*. 2025 Sep 8. doi: 10.1002/ijc.70127. Online ahead of print. Impactfactor: 4,7

Lunenberg RA, Franken IA, Braat MN, **Elferink MA**, van der Baan FH, Koopman M, **Vink G**, Intven MP, **Sijtsma FP**, Roodhart JM. The impact of mismatch repair status on accuracy of clinical staging in stage II/III rectal cancer in daily practice. *Eur J Cancer*. 2025 Nov 14;232:116117. doi: 10.1016/j.ejca.2025.116117. Online ahead of print. Impactfactor: 7,1

Rubio-Alarcón C, Georgiadis A, Franken IA, Wang H, van Nassau SC, Schraa SJ, van der Kruijssen DE, van Rooijen K, Linders TC, Delis-van Diemen P, Alkemade M, Boliijn A, Tijssen M, Lemmens M, Meiqari L, Ketelaars SL, Closa-Mosquera A, van Dongen MM, Lanfermeijer M, Lissenberg-Witte BI, Bosch LJ, Bisschop-Snetselaar T, Adriaans BC, Greer A, Riley D, White JR, Greco C, Cox L, Fox J, Victor K, Leech C, Angiuoli SV, Kok NF, Punt CJ, van den Broek D, Koopman M, Meijer GA, Velculescu VE, Roodhart JM, Coupé VM, Sausen M, **Vink GR**, Fijneman RJ; Other Members of the PLCRC-MEDOCC Group. Circulating tumour DNA in patients with stage III colon cancer: multicentre prospective PROVENC3 study. *Br J Surg*. 2025 Dec 24;113(1):znaf281. doi: 10.1093/bjs/znaf281. Impactfactor: 8,8

Schafrat PJ, **van Erning FN**, Zwinderman K, Dekker E, Farina Sarasqueta A, de Vos-Geelen J, Bouwense SA, Goedegebuure RS, Vermeulen L, de Hingh IH, Sommeijer DW. Malignancies of the small intestine: incidence and trends in a nationwide registry. *Cancer Epidemiol*. 2025 Oct 16;99:102943. doi: 10.1016/j.canep.2025.102943. Online ahead of print. Impactfactor: 2,3

van den Berg K, **van Erning FN**, Burger JW, van Hellemond IE, Roodhart JM, Koopman M, Rutten HJ, Creemers GJ. Treatment adherence to adjuvant chemotherapy according to the New Standard 3-month CAPOX regimen in high-risk stage II and stage III colon cancer: a population-based evaluation in the Netherlands. *Clin Colorectal Cancer*. 2025 Mar 1:S1533-0028(25)00027-1. doi: 10.1016/j.clcc.2025.02.006. Online ahead of print. Impactfactor: 3,2

**van den Heuvel TB, van Erning FN**, Hemmer PH, Madsen EV, de Reuver PR, Wiezer RJ, Witkamp AJ, **de Hingh IH**. Recurrence patterns following CRS-HIPEC in patients with colorectal peritoneal metastases: insights from the Dutch CRS-HIPEC registry. *Eur J Surg Oncol*. 2025 Oct 9;51(12):110501. doi: 10.1016/j.ejso.2025.110501. Online ahead of print. Impactfactor: 2,9

van Erning FN, Galanos LJ, Lurvink R, Aarts MJ, van Hellemond IE, Nagtegaal ID, de Hingh IH, de Wilt JH, Elferink MA. Socioeconomic differences among patients with stage I-III colon cancer: detection, treatment and relative survival. *Int J Cancer*. 2025 Oct 2. doi: 10.1002/ijc.70181. Online ahead of print. Impactfactor: 4,7

van Gansewinkel EH, van den Heuvel TB, van Erning FN, de Hingh IH, Bouwense SA, Simkens GA. Combined peritoneal and liver metastases in colorectal cancer: a Dutch nationwide population-based analysis of incidence, treatment and survival. *Eur J Surg Oncol*. 2025 Mar 25;51(7):109999. doi: 10.1016/j.ejso.2025.109999. Online ahead of print. Impactfactor: 2,9

van Nassau SC, Zwart K, van der Baan FH, Vink GR, Elferink MA, Snaebjornsson P, May AM, Koopman M, Roodhart JM. Real-world treatment patterns and outcomes based on RAS/BRAF status in metastatic colorectal cancer: analysis of the Prospective Dutch Colorectal Cancer cohort. *Int J Cancer*. 2025 Mar 13. doi: 10.1002/ijc.35410. Online ahead of print. Impactfactor: 4,7

Vande Kerckhove FE, van den Berg K, van Erning FN, Daniels-Gooszen AW, Verrijssen AE, Peulen HM, Rutten HJ, van Hellemond IE, Bloemen JG, Burger JW, Nederend J, Tolenaar JL, Ketelaers SH. Implications of inaccurate lymph node staging in early and intermediate-risk rectal cancer on survival-related outcomes in a large Dutch population-based cohort. *Eur J Cancer*. 2025 Oct 20:116052. doi: 10.1016/j.ejca.2025.116052. Online ahead of print. Impactfactor: 7,1

Wang H, Kramer A, Greuter MJ, Rubio-Alarcón C, Lissenberg-Witte B, Meijer GA, Kok NF, van den Broek D, Vink GR, Roodhart JM, Sausen M, Fijneman RJ, Coupé VM. CtDNA-guided de-escalation of adjuvant chemotherapy in stage III colon cancer: early model-based evaluation of cost-effectiveness. *Ther Adv Med Oncol*. 2025 Nov 6;17:17588359251384238. doi: 10.1177/17588359251384238. eCollection 2025. Impactfactor: 4,2

Wu W, Mols F, Bonhof CS, Maas L, van Schooten FJ, Hageman GJ, van de Poll-Franse LV, Schoormans D. Association of ageing-related biomarkers with peripheral neuropathy in colorectal cancer patients up to 2 years after diagnosis. *PLoS One*. 2025 Sep 26;20(9):e0332579. doi: 10.1371/journal.pone.0332579. eCollection 2025. Impactfactor: 2,6

## 4.2 Overige publicaties

Elferink MA, Galanos LJ, Sijtsma FP, Bijlsma MJ, Buffard TE, de Hingh HJ, van Leerdam ME, van Erning FN. Incidentie van darmkanker stijgt bij jonge mensen in Nederland: reden tot zorg. *NtvG* 169(2025)5(mei); 19-23.

Pennings AJ, Vink GR, van Kuijk S, Melenhorst J, Beets GL, May AM, Breukink SO. Betere functionele uitkomsten na rectumcarinoom: ook de kwaliteit van leven nam toe sinds 2014. *NtvG* 169(2025)6(juni);22-25.

## 4.3 Proefschriften en promoties

de Nes LC. Assessment and improvement of quality of care in colorectal cancer surgery. Nijmegen: Radboud Universiteit; 13 juni 2025. Promotor: JH de Wilt. Copromotor: RH Verhoeven.

Hamers P. Prognostication for patients with colorectal cancer: using real-world data. Utrecht: Universiteit; 27 maart 2025. Promotoren: M Koopman, AM May. Copromotoren: GR Vink.

van der Ven RG. The complexity of multi-hospital oncology networks: a widely used and promising structure without a blueprint. Maastricht: Maastricht Universiteit; 16 december 2025. Promotoren: IH de Hingh, AT Paulus. Co-supervisors: DD Westra, FN van Erning. Assessment committee: D Ruwaard, MA van der Aa, R van der Hulst, N van der Meer.

## 5 Gynaecologische tumoren

### 5.1 Publicaties met impactfactor

Castañeda KM, Vermeulen KM, [van der Aa MA](#), Schuurung E, Wisman GB, de Bock GH. Trends in cervical cancer incidence in the Netherlands: a join-point and age-period-cohort analysis (1989-2023). *Int J Cancer*. 2025 Sep 8. doi: 10.1002/ijc.70134. Online ahead of print. Impactfactor: 4,7

[Ebben KC](#), de Kroon CD, Schmeink CE, [van der Hel OL](#), [van Vegchel T](#), [Thissen M](#), de Hingh IH, [van der Werf J](#). Leveraging real-world data for continuous evaluation of computational clinical practice guidelines. *BMJ Health Care Inform*. 2025 May 12;32(1):e101333. doi: 10.1136/bmjhci-2024-101333. Impactfactor: 4,4

Hardie AN, [Wenzel HH](#), Schnack TH, [van der Aa MA](#), Jensen PT, Bekkers RM, Falconer H; Dutch, dANish and swedish gynaEcoLogical ONcology (DANDELION) research group. Oncological outcomes after radical hysterectomy followed by adjuvant (chemo)radiation or no further treatment in women with cervical cancer FIGO 2018 IB2-IIA2: a multinational population-based cohort study. *Eur J Cancer*. 2025 Jul 29;227:115664. doi: 10.1016/j.ejca.2025.115664. Online ahead of print. Impactfactor: 7,1

Hardie AN, [Wenzel HH](#), Schnack TH, [van der Aa MA](#), Jensen PT, Bekkers RL, Falconer H; Dutch, dANish and swedish gynaEcoLogical ONcology (DANDELION) research group. Response to Letter Re: Oncological outcomes after radical hysterectomy followed by adjuvant (chemo)radiation or no further treatment in women with cervical cancer FIGO 2018 IB2-IIA2- a multinational population-based cohort study. *Eur J Cancer*. 2025 Aug 25;228:115743. doi: 10.1016/j.ejca.2025.115743. Online ahead of print. Impactfactor: 7,1

Laven P, [Wenzel HH](#), [van der Aa MA](#), Lambrechts S, Kruitwagen RF. Impact of lymph node dissection and adjuvant chemotherapy on survival of patients with early-stage ovarian cancer: update of a national cohort study. *Gynecol Oncol*. 2025 Jul 21;200:51-57. doi: 10.1016/j.ygyno.2025.07.010. Online ahead of print. Impactfactor: 4,1

Lombaers MS, Vrede SW, Reijnen C, Boll D, Visser NC, Pijnenborg JM, [Ezendam NP](#), Hermens RP. Implementation of a personalized risk model for lymph node metastasis in endometrial carcinoma: healthcare providers' perspectives on use, barriers, and facilitators. *Cancer Med*. 2025 Aug;14(15):e71103. doi: 10.1002/cam4.71103. Impactfactor: 3,1

[Olthof EP](#), [Wenzel HH](#), van der Velden J, Stalpers LJ, [van der Aa MA](#), Mom CH. Adjuvant chemoradiotherapy or radiotherapy alone for early squamous cervical cancer with a single surgical-pathological high-risk factor. *Cancers (Basel)*. 2025 Jun 18;17(12):2041. doi: 10.3390/cancers17122041. Impactfactor: 4,4

[Olthof EP](#), [Oostveen NA](#), [van der Aa MA](#), Bekkers RL, Mom CH, van der Velden J, Nederend J, van Esch EM. Prognostic and therapeutic implications of clinical-radiologic discrepancy in parametrial invasion prior to primary radical hysterectomy in cervical cancer. *Gynecol Oncol Rep*. 2025 Dec 9;63:102002. doi: 10.1016/j.gore.2025.102002. eCollection 2026 Feb. Impactfactor: 1,3

[Olthof EP](#), [Wenzel HH](#), [van Maaren MC](#), van der Velden J, Spijkerboer AM, Bekkers RL, Beltman JJ, Slangen BF, Nijman HW, Smolders RG, van Trommel NE, Zusterzeel PL, Zweemer RP, Stalpers LJ, [van der Aa MA](#), Mom CH. Radical hysterectomy or chemoradiotherapy for clinically early-stage cervical cancer with suspicious lymph nodes on imaging: a retrospective cohort study. *J Gynecol Oncol*. 2025 Mar;36(2):e16. doi: 10.3802/jgo.2025.36.e16. Impactfactor: 3,7

Rütten H, [Wenzel HH](#), Ten Eikelder M, Simons M, [van der Aa MA](#), Bussink J, Pijnenborg JM. Impact of patient characteristics on primary treatment approach of endometrial cancer: a population-based study in

the Netherlands. *Int J Gynecol Cancer*. 2025 Aug 5;35(10):102034. doi: 10.1016/j.ijgc.2025.102034. Online ahead of print. Impactfactor: 4,7

**Said SA**, IntHout J, Koffijberg H, de Hullu JA, Hyde SE, **van der Aa MA**, van Altena AM. External validation of prediction models for early relapse in advanced epithelial ovarian cancer using Australian and Dutch population-based data. *Cancer Epidemiol*. 2025 May 1;97:102824. doi: 10.1016/j.canep.2025.102824. Online ahead of print. Impactfactor: 2,3

van Erp MA, van Odenhoven AE, Burger JW, Ayez N, **Ezendam NP**, Boll D, Smedts HP, Piek JM. Enhancing multidisciplinary collaboration in ovarian cancer surgery. *Int J Gynecol Cancer*. 2025 Jan;35(1):100014. doi: 10.1016/j.ijgc.2024.100014. Epub 2024 Dec 17. Impactfactor: 4,7

**Vermaas EM**, Van Lonkhuijzen LR, Westerveld H, **van der Aa MA**, Bonestroo TJ, Slangen BF, Aarts JW. Patient voices: what can we learn from the Covid-19 pandemic about follow-up care in gynaecologic oncology? *Health Expect*. 2025 Oct;28(5):e70405. doi: 10.1111/hex.70405. Impactfactor: 3,2

**Vermaas EM**, de Rooij I, Cohen ES, van Hoogstad JS, Hehenkamp WJK, Aarts JW. Patients' and medical specialists' attitudes on follow-up care and climate impact in gynaecological oncology: a nationwide survey. *Eur J Obstet Gynecol Reprod Biol*. 2025 Nov 26;317:114858. doi: 10.1016/j.ejogrb.2025.114858. Online ahead of print. Impactfactor: 1,9

**Vermaas EM**, Röling P, Konior KM, **Wenzel HH**, **van der Aa MA**, Boll D, van Lonkhuijzen LR, Aarts JW. Reconsidering follow-up care in gynaecologic oncology: a scoping review exploring alternative approaches. *Gynecol Oncol*. 2025 Nov 3;203:139-150. doi: 10.1016/j.ygyno.2025.10.024. Online ahead of print. Impactfactor: 4,1

Wolswinkel JT, Zusterzeel PL, Smits A, Siebers AG, **Wenzel HH**, Bekkers RL, Beltman JJ, Lok CA, Mom CH, van Trommel NE, Zweemer RP, Maurits JS, Ten Eikelder ML. Survival after fertility-sparing surgery for early-stage cervical cancer compared with nonsparing surgery: a nationwide comparative study. *JCO Oncol Pract*. 2025 Sep 23;OP2500131. doi: 10.1200/OP-25-00131. Online ahead of print. Impactfactor: 4,7

**Ye Y**, **Timmermans M**, **van der Aa MA**, le Cessie S, Jonges GN, Janse JA, Gerestein CG. Effect of uterine manipulator on oncologic outcome in early-stage, low-grade endometrial cancer. *Int J Gynecol Cancer*. 2025 Feb;35(2):100047. doi: 10.1016/j.ijgc.2024.100047. Epub 2024 Dec 18. Impactfactor: 4,7

## 5.2 Proefschriften en promoties

**Said SA**. Towards personalized care in advanced epithelial ovarian cancer: treatment response and predictors of survival. Nijmegen: Radboud Universiteit; 22 september 2025. Promotor: JA de Hullu. Copromotoren: AM van Altena, **MA van der Aa**, J in 't Hout.

## 6 Hemato-oncologie

### 6.1 Publicaties met impactfactor

Al-Sarayfi D, Bult JA, de Groen RA, de Groot FA, Vermaat JS, Issa D, Diepstra A, Huls G, Bellido M, Plattel W, **Brink M**, Nijland M. Non-inferior outcome of abbreviated R-CHOP in patients with stage I primary testicular lymphoma. *Eur J Cancer*. 2025 Sep 12;229:115776. doi: 10.1016/j.ejca.2025.115776. Online ahead of print. Impactfactor: 7,1

de Groot FA, Stedema FG, Kret EJ, de Haan LM, Jansen PM, Böhringer S, Diepstra A, van der Poel MW, Hamid MA, te Boome LC, Terpstra V, **Brink M**, Veelken H, de Groen RA, Dekker TJ, Nijland M, Vermaat JS. MATRix and HD-MTX/IFO/DEP treatment and autologous stem cell transplantation in secondary central nervous system lymphoma: a Dutch retrospective analysis. *Haematologica*. 2025 May 29. doi: 10.3324/haematol.2025.287485. Online ahead of print. Impactfactor: 7,9

Hermans SJ, Versluis J, van Werkhoven ED, van Norden Y, Janssen JJ, Huls GA, Pabst T, Breems DA, Berkx E, **Dinmohamed AG**, **Huijgens PC**, Sträng E, Hernández Rivas JM, Sobas M, Ayala Diaz R, Martinez Lopez J, Metzeler KH, Haferlach T, Thiede C, Uyl-de Groot CA, Bullinger L, Löwenberg B, Ossenkoppele GJ, Pignatti F, Cornelissen JJ. Comparability of external and internal control patients for the prospective randomized HOVON-103 trial in older AML patients. *Br J Haematol*. 2025 May 26. doi: 10.1111/bjh.20185. Online ahead of print. Impactfactor: 3,9

Hofsink Q, Lissenberg-Witte BI, Haggenburg S, Goorhuis A, Hazenberg MD, Rutten CE, den Tex P, de Vries EG, van der Veldt AA, Kemmeren JM, de Keizer NF, **Huijgens PC**, **Dinmohamed AG**, van Roon A, Pijpers J, van Roekel C, van den Hof S, Hahné SJ, de Gier B, Heijmans J, Nijhof IS. COVID-19 vaccine effectiveness in patients with hematologic malignancies: a nationwide cohort study. *J Infect Dis*. 2025 Oct 14;jjaf523. doi: 10.1093/infdis/jiaf523. Online ahead of print. Impactfactor: 4,5

**Kaplan ZL**, van Leeuwen N, van Klaveren D, Eijkenaar F, **Visser O**, Posthuma EF, Zweegman S, Huls G, van Rhenen A, Blijlevens NM, Cornelissen JJ, van de Loosdrecht AA, Pruijt JH, Levin MD, Hoogendoorn M, Lemmens VE, Lingsma HF, **Dinmohamed AG**. The association between hospital volume and overall survival in adult AML patients treated with intensive chemotherapy. *ESMO Open*. 2025 Jan 30;10(2):104152. doi: 10.1016/j.esmoop.2025.104152. Online ahead of print. Impactfactor: 8,3

Klomberg KM, Gelderloos M, Kooistra HA, Nijland M, de Bock GH, Huls GA, **Brink M**, Roeloffzen WW, Plattel WJ. Real-world outcomes of high dose melphalan and autologous stem cell transplantation in patients with multiple myeloma older and younger than 65 years. *Clin Lymphoma Myeloma Leuk*. 2025 Dec 18:S2152-2650(25)04302-2. doi: 10.1016/j.clml.2025.12.007. Online ahead of print. Impactfactor: 2,7

Linschoten M, Geels J, van Werkhoven E, Visser-Wisselaar H, Chamuleau ME, Teske AJ, Robbers L, **Oerlemans S**, Crommelin H, Breems-de Ridder M, Schut A, Asselbergs FW, van Rhenen A; HOVON 170 DLBCL – ANTICIPATE consortium. Rationale and design of the HOVON 170 DLBCL-ANTICIPATE trial: preventing anthracycline-induced cardiac dysfunction with dexrazoxane. *Cardiooncology*. 2025 Jan 28;11(1):8. doi: 10.1186/s40959-025-00303-y. Impactfactor: 3,2

Meeuwes FO, **Brink M**, van der Poel MW, Serroukh YI, Vermaat JS, Huls GA, de Boer M, de Jong D, Plattel WJ, Nijland M. Treatment and outcome of breast implant-associated anaplastic large cell lymphoma: a population-based cohort study in the Netherlands. *Leuk Lymphoma*. 2025 Jul 9:1-7. doi: 10.1080/10428194.2025.2530167. Online ahead of print. Impactfactor: 2,2

Metsemakers SJ, Ector GI, **Dinmohamed AG**, Hermens RP, Blijlevens NM. Real-world decline in survival with poor guideline adherence in chronic myeloid leukemia care. *Blood Cancer J*. 2025 Nov 24;15(1):205. doi: 10.1038/s41408-025-01423-5. Impactfactor: 11,6

Neppelenbroek SI, **Ekels A**, Kersten MJ, Issa DE, Thielen N, **van de Poll-Franse LV**, **Oerlemans S**. Fatigue, neuropathy and psychological distress and their association with health-related quality of life in survivors of diffuse large B-Cell lymphoma: a prospective cohort study and comparison with a normative population. *Hematol Oncol*. 2025 Nov;43(6):e70151. doi: 10.1002/hon.70151. Impactfactor: 3,9

Nijland M, Issa DE, Bult JA, Deeren D, Velders GA, Nijziel MR, Sandberg Y, Vergote VK, Oosterveld M, Fijnheer R, Brouwer R, Boersma R, Wu K, Nieuwenhuizen L, Vermaat JS, van Kampen RJ, Terpstra WE, Snauwaert S, van der Poel MW, de Jongh E, Durian M, Strobbe L, Beeker A, Gadisseur AP, van Rijn R, Visser OJ, Doorduijn J, Snijders TJ, Silbermann MH, de Jong D, Chamuleau ME, Mous R, Jalving M, Visser-Wisselaar H, Jansen van den Bergh S, Zwezerijnen GJ, Bremer E, **Brink M**, Diepstra A, Chitu DA, Koene HR, Zijlstra JM. Atezolizumab consolidation in patients with high risk diffuse large B-cell lymphoma in complete remission after R-CHOP. *Blood Adv*. 2025 Apr 18:bloodadvances.2024015226. doi: 10.1182/bloodadvances.2024015226. Online ahead of print. Impactfactor: 7,1

Pennings ER, Spanjaart AM, Thielen FW, **Oerlemans S**, Fleischer A, Sanges C, Gomes Da Silva M, Cabrerizo Y, Lecot P, Roux-Opstaele L, Dreuillet C, Gonzalez-Marcano E, Millán O, Jaeger U, Delgado J, Luu M, Huber B, Lorrain M, Galhardas Pina M, Kremer A, Bolanos N, Clavreul S, Nier S, Liu RDK, Lissenberg-Witte BI, Anguille S, Robin M, Morris EC, Sureda A, Préau M, Pannard M, De Bock GH, Wagers SS, Trebeden-Negre H, Maucort-Boulch D, Hudecek M, Uyl-de Groot CA, Kersten MJ. Patient-reported outcomes in patients with hematologic malignancies treated with CAR T-cell therapy in Europe. *Blood Adv*. 2025 Sep 24:bloodadvances.2025017081. doi: 10.1182/bloodadvances.2025017081. Online ahead of print. Impactfactor: 7,1

Pothast CR, Hofsink Q, Haggenburg S, Dijkland RC, van de Meent M, van Dijk K, Bhoekhan MS, Haverkate NJ, van Meerloo J, Falkenburg JH, de Groen RA, Broers AE, van Doesum JA, van Binnendijk RS, den Hartog G, Lissenberg-Witte BI, Kater AP, Smits GP, Wouters D, van Leeuwen EM, Bontkes HJ, Kootstra NA, **Vogels-Nooijen S**, van Baarle D, de Vries RD, van Meerten T, Mutsaers PG, Goorhuis A, Nijhof IS, Hazenberg MD, Heemskerk MH, Rutten CE; COBRA KAI study team. T-cell and antibody responses in immunocompromised patients with hematologic malignancies indicate strong potential of SARS-CoV-2 mRNA vaccines. *Haematologica*. 2025 May 29. doi: 10.3324/haematol.2024.287136. Online ahead of print. Impactfactor: 7,9

Roshani S, van Leeuwen FE, Rossetti S, Hauptmann M, **Visser O**, Zijlstra JM, Hutchings M, Schaapveld M, Aleman BM. Predicting absolute risk of first relapse in classical Hodgkin lymphoma by incorporating contemporary treatment effects. *Cancers (Basel)*. 2025 Aug 24;17(17):2760. doi: 10.3390/cancers17172760. Impactfactor: 4,4

Salzbrunn JB, van Zeventer IA, de Graaf AO, Klätte S, van Pelt LJ, Kamphuis P, van Bergen MG, **Dinmohamed AG**, van der Reijden BA, Linssen J, Schuringa JJ, Jansen JH, Huls G. Clonal haematopoiesis associates with distinct cytometric changes of red blood cells and platelets. *Br J Haematol*. 2025 Aug 3. doi: 10.1111/bjh.70031. Online ahead of print. Impactfactor: 3,9

Trama A, Geerdes EE, Demuru E, de Angelis R, **Karim-Kos HE**, Troussard X, Bennett D, Marcos-Gragera R, Kuehni CE, Liu H, Bernasconi A, Vener C, Guevara M, Zwaan CM, Mayer-da-Silva A, Paapsi K, Ragusa R, Smith OP; EUROCARE-6 Working Group. Survival of European children, adolescents and young adults diagnosed with haematological malignancies in the period 2000-2013: results from EUROCARE-6, a population-based study. *Eur J Cancer*. 2025 Mar 1;222:115336. doi: 10.1016/j.ejca.2025.115336. Online ahead of print. Impactfactor: 7,1

**van den Berg BM, Heipon CS, Korf C**, van Rhenen A, **Posthuma EF**, van der Linden YM, Pasma HR, **Raijmakers NJH, Brom L**. Clinicians' experiences, perspectives, barriers, and facilitators of integrating palliative care into hematological malignancy care: a qualitative interview study. *Support Care Cancer*. 2025 Jul 18;33(8):697. doi: 10.1007/s00520-025-09715-z. Impactfactor: 3,0

van Lieshout R, Tick LW, Beckers EA, Biesbroek W, Custers S, Dieleman JP, Dijkstra M, Groenesteijn W, Heldens A, Hengeveld MM, Koene HR, Kranenburg S, van der Lee D, van der Put L, Rademakers N, Regelink JC, Regis M, Somer M, van Tilborg CJ, Westerweel PE, de Witte M, de Zeeuw S, Schouten HC, **Beijer S**. Associations of various medical nutrition therapy strategies with body composition, and physical and clinical outcomes in acute myeloid leukemia patients undergoing intensive remission-induction treatment: a multicenter prospective correlational study. *Clin Nutr ESPEN*. 2025 Mar 5:S2405-4577(25)00090-7. doi: 10.1016/j.clnesp.2025.02.028. Online ahead of print. Impactfactor: 2,6

Vener C, Lillini R, de Angelis R, Bonfarnuzzo S, Poirel HA, Trama A, **Visser O**, Troussard X, Marcos-Gragera R, Maynadié M, Demuru E, di Benedetto C, Johannesen TB, Solans M, Paapsi K, Guevara M, Mousavi SM, Blum M, von Moos R, Bennett D, Ragusa R, Guilloteau A, McShane CM, Rossi S, Sant M; EURO-CARE-6 Working Group (appendix pp 34-35). Long-term survival for myeloid neoplasms and national health expenditure: a EURO-CARE-6 retrospective, population-based study. *Eur J Cancer*. 2025 Jan 16;220:115231. doi: 10.1016/j.ejca.2025.115231. Online ahead of print. Impactfactor: 7,1

Wang S, Nijland M, Strobbe L, Oosterveld M, Boersma R, Koene H, Klerk C, de Jongh E, Koster A, Pruijt H, van der Poel M, van Werkhoven E, Zanders H, **Dinmohamed AG**, Pegtel M, Meek S, Stowell SL, Warinske H, Alizadeh AA, Kurtz DM, Chamuleau ME. Prospective validation of circulating tumor DNA measurable residual disease after first-line therapy in large B-Cell Lymphoma. *J Clin Oncol*. 2025 Dec 12;JCO2501712. doi: 10.1200/JCO-25-01712. Online ahead of print. Impactfactor: 43,4

**Zijlstra M, Snijders RA**, de Boer F, Chamuleau ME, **Fransen HP, Oerlemans S**, van der Padt-Pruijsten A, Posthuma EF, **Visser O**, Zweegman S, **Raijmakers NJ, Dinmohamed AG**. Factors and considerations in no-treatment decisions in patients with key hematological malignancies: a nationwide, population-based study in the Netherlands. *Eur J Haematol*. 2025 Jan 29. doi: 10.1111/ejh.14390. Online ahead of print. Impactfactor: 2,3

## 7 Hoofdhalskanker

### 7.1 Publicaties met impactfactor

Bisheshar SK, Dams ET, Chan M, Slagter-Menkema L, Basdew H, van der Sluis T, Mohamedradja-Taus RN, Ameeralli DP, Akrum RA, Sheorajpanday S, Mehilal R, van Leeuwaarde RS, Devriese LA, **van Dijk BA**, Willems SM, van der Vegt B, Breimer GE. Head and neck cancer in Suriname: an epidemiologic review of clinical and pathologic features of patients treated between 2009 and 2021. *JCO Glob Oncol*. 2025 Aug;11:e2500045. doi: 10.1200/GO-25-00045. Epub 2025 Aug 6. Impactfactor: 3,3

Padovan BV, Beenker M, Langendijk JA, van der Laan HP, **van Dijk BA**, de Bock GH, Plaat BE, de Graeff P, Festen S, Halmos GB. Integrated geriatric assessment and intervention in the head and neck oncology care pathway reduces adverse events and does not affect survival. *Oral Oncol*. 2025 Dec 6;172:107811. doi: 10.1016/j.oraloncology.2025.107811. Online ahead of print. Impactfactor: 3,9

Thienpondt J, Demuyck K, **Merckx MA**, Speksnijder CM. Factors influencing objective voice profile and speech intelligibility of patients after oral oncological treatment: a prospective cohort study. *Support Care Cancer*. 2025 Jul 31;33(8):731. doi: 10.1007/s00520-025-09793-z. Impactfactor: 3,0

van de Velde LJ, Breimer GE, Scheurleer WF, de Ridder M, Devriese LA, Braunius WW, de Bree R, **van Dijk BA**, Rijken JA. Sinonasal intestinal-type adenocarcinoma in the Netherlands: a nationwide study (2008-2022). *Head Neck*. 2025 Sep;47(9):2531-2540. doi: 10.1002/hed.28171. Epub 2025 Apr 22. Impactfactor: 2,2

van den Bovenkamp K, Halmos GB, Slagter-Menkema L, **van Dijk BA**, Yu S, Langendijk JA, van der Laan BF, Schuurung E, van der Vegt B. The association between clinical outcome and expression of DNMT1, 3A, and 3B in locally advanced laryngeal carcinomas treated by definitive radiotherapy. *Cancers (Basel)*. 2025 May 22;17(11):1741. doi: 10.3390/cancers17111741. Impactfactor: 4,4

**van der Ven RG**, **van Erning FN**, Westra DD, **de Hingh IH**, Paulus AT, Engelen SM, de Vries B, Nieuwenhuijzen GA; OncoZON network. Nationwide trends and the impact of an oncology hospital network on reducing the burden of thyroid cytology procedures. *Int J Cancer*. 2025 May 2. doi: 10.1002/ijc.35462. Online ahead of print. Impactfactor: 4,7

van Dijk SP, **Maas CC**, Alshangi A, van Driel MH, Feitsma EA, van Kinschot CM, Lončar I, van Noord C, Koppert LB, Kruijff S, van Klaveren D, Verhoef C, Peeters RP, van Ginhoven TM; Hypoparathyroidism Study Group of the Thyroid Network. Development and validation of a prognostic model for persistent hypoparathyroidism after total or completion thyroidectomy. *Clin Otolaryngol*. 2025 Oct 2. doi: 10.1111/coa.70039. Online ahead of print. Impactfactor: 1,5

## 8 Huidkanker

### 8.1 Publicaties met impactfactor

Bramer EM, Chia C, Rentroia-Pacheco B, Tokez S, Pijnenborg L, Damman J, Amir A, Kumar D, **Hollestein LM**, Mooyaart AL, Wakkee M. Enhancing early detection of metastatic Cutaneous Squamous Cell Carcinoma (CSCC): integrating AI with histopathological assessments. *Exp Dermatol*. 2025 Jul;34(7):e70135. doi: 10.1111/exd.70135. Impactfactor: 3,1

Eggermont CJ, Hollatz A, Wakkee M, **Louwman M, Dinmohamed AG**, Posthuma EF, Nijsten T, **Hollestein L**. Skin cancer risk in over 200.000 patients with haematologic malignancies in 30 years; a nationwide population-based study in the Netherlands. *Br J Dermatol*. 2025 Jan 24:ljaf027. doi: 10.1093/bjd/ljaf027. Online ahead of print. Impactfactor: 10,6

**Hollestein LM**, Eggermont CJ, **Louwman MW, Schreuder K, Drissen MC**, Steijlen OF, Mooyaart AL, Bruggink AH, Voorham QJ, Grunhagen DJ, Jalving M, Nijsten TE, Wakkee M. Longitudinal data on advanced cutaneous squamous cell carcinoma from the Dutch Keratinocyte Cancer Collaborative (DKCC): a nationwide real-world database study. *Lancet Reg Health Eur*. 2025 Oct 18;59:101501. doi: 10.1016/j.lanpe.2025.101501. eCollection 2025 Dec. Impactfactor: 13,0

Janssen JC, Schurink AW, Verhoef C, Oomen-de Hoop E, **Louwman MW**, Grunhagen DJ, van der Veldt AA. 4-year overall survival after the introduction of adjuvant therapy for patients with stage III melanoma: a population-based study. *Eur J Cancer*. 2025 Dec 26:116202. doi: 10.1016/j.ejca.2025.116202. Online ahead of print. Impactfactor: 7,1

Ouwerkerk J, Kerkour T, Mooyaart A, Zhou C, Boers R, Boers J, Gribnau J, Wakkee M, Li Y, **Hollestein L**. Genome-wide methylation profiles of primary and matched distant metastasis: insights from the Dutch Early-Stage melanoma (D-ESMEL) study. *Hum Genomics*. 2025 Dec 6. doi: 10.1186/s40246-025-00871-1. Online ahead of print. Impactfactor: 4,3

Steijlen OF, Pozza L, Traets JJ, Rentroia-Pacheco B, Eggermont CJ, Bellomo D, Alex S, Patel VA, Mooyaart AL, **Hollestein LM**, Wakkee M. Enhanced metastatic risk stratification for cutaneous squamous cell carcinoma by combining clinical guidelines with the Erasmus MC model: results from two nationwide nested case-control studies. *J Am Acad Dermatol*. 2025 May 16:S0190-9622(25)02129-2. doi: 10.1016/j.jaad.2025.05.1390. Online ahead of print. Impactfactor: 11,8

Steijlen OF, Pozza L, Traets JJ, Rentroia-Pacheco B, Eggermont CJ, Bellomo D, Alex S, Patel VA, Mooyaart AL, **Hollestein LM**, Wakkee M. Response to [Zheng et al.] "Letter to "Enhanced metastatic risk stratification for Cutaneous Squamous Cell Carcinoma by combining clinical guidelines with the Erasmus MC model". *J Am Acad Dermatol*. 2025 Aug 29:S0190-9622(25)02704-5. doi: 10.1016/j.jaad.2025.08.069. Online ahead of print. Impactfactor: 11,8

Zhou C, Mooyaart AL, Kerkour T, **Louwman MW**, Wakkee M, Li Y, Voorham QJM, Bruggink A, Nijsten TE, **Hollestein LM**. The Dutch Early-Stage Melanoma (D-ESMEL) study: a discovery set and validation cohort to predict the absolute risk of distant metastases in stage I/II cutaneous melanoma. *Eur J Epidemiol*. 2025 Jan 9. doi: 10.1007/s10654-024-01188-4. Online ahead of print. Impactfactor: 5,9

## 9 Longkanker

### 9.1 Publicaties met impactfactor

Choudhury A, Volmer L, **Martin F**, Fijten R, Wee L, Dekker A, Soest JV. Advancing privacy-preserving health care analytics and implementation of the personal health train: federated deep learning study. JMIR AI. 2025 Feb 6;4:e60847. doi: 10.2196/60847.  
Impactfactor: 2,0

de Nijs K, ten Haaf K, Moldovanu D, Hubert J, van den Bosch I, **Eijkelboom A**, van der Aalst C, de Koning HJ. Influence of changing patterns in lung cancer treatment and survival on the cost-effectiveness of CT screening: a modeling study. EClinicalMedicine. 2025 Aug 29;88:103446. doi: 10.1016/j.eclinm.2025.103446. eCollection 2025 Oct.  
Impactfactor: 10,0

**Eijkelboom AH**, d'Hooghe JN, van der Sangen M, van den Heuvel MM, Kroeze LI, Marres GM, Kunst PW, **Aarts MJ**. Income inequalities, tumor stage at diagnosis, and treatment in patients with non-small cell lung cancer: a population-based study in the Netherlands. Int J Cancer. 2025 Nov 7. doi: 10.1002/ijc.70230. Online ahead of print.  
Impactfactor: 4,7

Heijboer FW, Brambilla M, Occhipinti M, Lorenzini D, Buikhuisen WA, Kodach LL, Christopoulos P, Stenzinger A, Hillen LM, Garrido P, Lage Y, Benito A, Lindsay CR, Carter M, Herder J, Britstra R, van der Drift MA, de Jong WK, Schutgens FW, **Damhuis RM**, Speel EM, von der Thüsen JH, Dingemans AC, Derks JL. Actionable genomic alterations in large cell neuroendocrine carcinoma: a European case series of patients treated with a small molecule inhibitor. JCO Precis Oncol. 2025 Nov;9:e2500293. doi: 10.1200/PO-25-00293. Epub 2025 Nov 14.  
Impactfactor: 5,8

Heijboer FW, Derks JL, van Nederveen FH, Hillen LM, den Bakker MA, Radonic T, **Damhuis RA**; PALGA-Group. Treatment outcomes in patients with stage IV large cell neuroendocrine carcinoma: a nationwide registry study. Lung Cancer. 2025 Nov 7;210:108830. doi: 10.1016/j.lungcan.2025.108830. Online ahead of print.  
Impactfactor: 4,4

Houda I, Naves D, Ulas EB, Lissenberg-Witte BI, Barlo NP, Kastelijns EA, Bouhaddou H, Shaikh R, Dickhoff C, Radonic T, Schneiders FL, Senan S, **Damhuis RA**, Bahce I. Survival outcomes with carboplatin versus cisplatin and the impact of COVID-19 on platinum choice: a nationwide Netherlands registry study in small cell lung cancer patients (CACIS). Eur J Cancer. 2025 Oct 2;230:116042. doi: 10.1016/j.ejca.2025.116042. Online ahead of print.  
Impactfactor: 7,1

Huijs JW, Ogliari FR, **Damhuis RA**, Jongbloed M, Broen MP, Anten MH, Brandsma D, Degens JH, De Ruyscher DK, Hendriks LE. Overall survival in patients with non-small cell lung cancer and leptomeningeal metastases: data from the Dutch cancer Registry. Lung Cancer. 2025 Oct 25;209:108806. doi: 10.1016/j.lungcan.2025.108806. Online ahead of print.  
Impactfactor: 4,4

Jongbloed M, **Damhuis RA**, van Geffen WH, de Boer P, Huijs JW, Dursun S, Degens J, van den Borne BE, Soud MY, Steens M, Pitz C, de Ruyscher DK, Hendriks LE. Effect of treatment sequencing on outcome of patients with non-small cell lung cancer with a synchronous solitary extrathoracic metastasis. Lung Cancer. 2025 Dec 25;212:108889. doi: 10.1016/j.lungcan.2025.108889. Online ahead of print.  
Impactfactor: 4,4

**Katsimpokis D**, **Aarts MJ**, **Geleijnse G**, Kunst P, **Bijlsma MJ**. Income inequality and access to advanced immunotherapy for lung cancer: the case of Durvalumab in the Netherlands. J Clin Epidemiol. 2025 Feb 4;111711. doi: 10.1016/j.jclinepi.2025.111711. Online ahead of print.  
Impactfactor: 5,2

---

Miguel JW, van Veen NL, Jacobs W, **Damhuis RA**, van Uden-Kraan CF, van de Garde EM; Santeon VB Lung Cancer Research Group. [Applied first-line systemic treatments, treatment modifications and outcomes in non-oncogenic metastatic non-small cell lung cancer in the Netherlands in 2019-2020: a nationwide study](#). *Cancer Epidemiol.* 2025 Apr 4;96:102809. doi: 10.1016/j.canep.2025.102809. Online ahead of print.

Impactfactor: 2,3

Smesseim I, Douma LH, Burgers JA, **Damhuis RA**. [Pleural mesothelioma incidence and use of systemic treatment decreased during the COVID-19 pandemic in The Netherlands](#). *Sci Rep.* 2025 Jul 16;15(1):25677. doi: 10.1038/s41598-025-10054-6.

Impactfactor: 3,9

van Vuren RM, Wolfhagen N, **Damhuis RA**, Kruijff S, van der Plas WY, Schreurs WH, Schuurbiens OC, Smit HJ, Verhagen AF, Wouters MW, Belderbos J, Heineman DJ. [Impact of COVID-19 pandemic on treatment patterns for stage I non-small cell lung cancer in the Netherlands](#). *Cancer Treat Res Commun.* 2025 Dec 3;46:101061. doi: 10.1016/j.ctarc.2025.101061. Online ahead of print.

Impactfactor: 2,4

## 10 Neuro-oncologie

### 10.1 Publicaties met impactfactor

**Ho VK**, Gijtenbeek JM, Maas SN, Taal W, van Linde ME, Broen MG, van Rij CM, van der Weide HL, Wagemakers M, ter Laan M, de Vos FY, Bromberg JE; Dutch Society for Neuro-Oncology (LWNO). *Adult ependymoma: results from the Dutch Brain Tumour Registry on primary treatment and survival*. J Neurooncol. 2025 Nov 5;176(1):73. doi: 10.1007/s11060-025-05278-5. Impactfactor: 3,1

Hoogendijk R, Capocaccia R, van der Lugt J, Kranendonk ME, Hoving EW, Wesseling P, **Visser O**, van Vuurden DG, Gatta G, **Karim-Kos HE**; EUROCARE working group. *Long-term survival and cure fraction estimates for paediatric central nervous system tumours in 31 European countries (EUROCARE-6): a population-based study*. Lancet Oncol. 2025 Aug;26(8):1091-1099. doi: 10.1016/S1470-2045(25)00297-9. Impactfactor: 35,9

van Dijck JT, Ardon H, Balvers RK, Bos EM, Bosscher L, Brouwers HB, **Ho VK**, Hovinga K, Kwee L, ter Laan M, Nabuurs RJ, Robe PA, van Geest S, van der Veer O, Verburg N, Wagemakers M, de Witt Hamer PC, Rodriguez Gironde M, Nandoe Tewarie RD; Quality Registry Neuro Surgery glioblastoma working group from the Dutch Society of Neurosurgery. *Survival prediction in glioblastoma: 10-year follow-up from the Dutch Neurosurgery Quality Registry*. J Neurooncol. 2025 May 23. doi: 10.1007/s11060-025-05080-3. Online ahead of print. Impactfactor: 3,1

Viozzi I, Hannink G, Ardon H, Balvers RK, Bosscher L, van Geest S, **Ho VK**, Hovinga K, Kwee L, Tewarie RN, Robe PA, van der Veer O, Wagemakers M, ter Laan M, de Witt Hamer PC. *Between-hospital variation in biopsy indication for patients with newly diagnosed glioblastoma in the Dutch Quality Registry for Neurosurgery*. J Neurooncol. 2025 Feb 6. doi: 10.1007/s11060-025-04959-5. Online ahead of print. Impactfactor: 3,1

# 11 Upper GI & HPB

## 11.1 Publicaties met impactfactor

Bogdanski AM, Klatter DC, Laghari SI, Langers AM, Das A, Bastiaansen BA, Bonsing BA, Dekker E, van Hooft JE, Samadder JN, Brosens LA, [van der Geest LG](#), Boardman L, Nielsen M, van Kouwen MC, Bisseling TM, Wallace MB, Riegert-Johnson D, van Leerdam ME; Dutch Pancreatic Cancer Group. **Pancreatic cancer surveillance not recommended for familial adenomatous polyposis: a fine and gray risk analysis.** *Fam Cancer.* 2025 Nov 25;24(4):88. doi: 10.1007/s10689-025-00512-5.

Impactfactor: 2,0

Broekman TH, Augustinus S, Biesma N, Bonsing BA, Cirkel GA, de Hingh IH, Homs MY, van Hooft JE, van der Kolk BM, de Meijer VE, van Santvoort H, de Vos-Geelen J, Wumkes ML, Besselink MG, Wilmink JH, [van der Geest LG](#); Dutch Pancreatic Cancer Group. **Regional variation for tumour-directed treatment and survival in patients with pancreatic adenocarcinoma: a nationwide population-based analysis.** *HPB (Oxford).* 2025 Dec 30:S1365-182X(25)01772-1. doi: 10.1016/j.hpb.2025.12.035. Online ahead of print.

Impactfactor: 2,4

Doeve BH, Kuijper SC, Silversmit G, van Walle L, Nafteux P, Rosman C, [Vissers PA](#), Jeene P, Beerepoot LV, Derks S, Karimi A, Bijlsma MF, van Laarhoven HW, [Verhoeven RH](#). **Treatment and survival of patients with esophageal and gastric cancer in the Netherlands and Belgium: a population-based comparison.** *Int J Cancer.* 2025 Nov 19. doi: 10.1002/ijc.70225. Online ahead of print.

Impactfactor: 4,7

Furumaya A, Gumede A, Weeda VB, Cillessen S, [van der Geest LG](#), Erdmann J, Takkenberg RB, Doukas M, de Vos-Geelen J, Verheij J; Dutch Hepatocellular & Cholangiocarcinoma Group (DHCG). **Correct diagnosis of patients with fibrolamellar carcinoma: a Dutch nationwide study.** *Histopathology.* 2025 Dec 28. doi: 10.1111/his.70068. Online ahead of print.

Impactfactor: 4,1

Geerts JF, [Vissers PA](#), Mostert B, Wijnhoven BP, Haberkorn BC, Anten MG, Rosman C, Creemers GJ, Westdorp H, van der Sangen MJ, [Verhoeven RH](#), Nieuwenhuijzen GA. **Hospital variation in treatment for synchronous metastatic esophageal and gastric cancer: a nationwide population-based study in the Netherlands.** *Int J Cancer.* 2025 Jun 5. doi: 10.1002/ijc.35491. Online ahead of print.

Impactfactor: 4,7

Gehrels AM, [Vissers PA](#), Sprangers MA, Fijnheer NM, Pijnappel EN, [van der Geest LG](#), Cirkel GA, de Vos-Geelen J, Homs MY, Creemers GJ, Stommel MW, Daamen LA, Besselink MG, Wilmink JW, van Laarhoven HW. **Longitudinal health-related quality of life in patients with pancreatic cancer stratified by treatment: a nationwide cohort study.** *EClinicalMedicine.* 2025 Jan 21;80:103068. doi: 10.1016/j.eclinm.2024.103068. eCollection 2025 Feb.

Impactfactor: 10,0

Impactfactor: 10,0

Graus MU, van Diepen AE, Josemanders K, Besselink MG, Bouwense SA, Daamen LA, de Hingh IH, de Jong EJ, van Laarhoven HW, de Meijer VE, Quintus Molenaar I, Stommel MW, Valkenburg-van Iersel LB, Wilmink JW, [van der Geest LG](#), de Vos-Geelen J; Dutch Pancreatic Cancer Group. **Patterns of disease dissemination and survival in patients with synchronous and metachronous metastatic pancreatic adenocarcinoma: nationwide population-based study.** *Eur J Cancer.* 2025 Mar 23;220:115385. doi: 10.1016/j.ejca.2025.115385. Online ahead of print.

Impactfactor: 7,1

Guchelaar NA, de Neijls MJ, Noordman BJ, Graaf HE, van Hellemond IE, van der Sluis PC, Hoop EO, Lagarde SM, [Verhoeven RH](#), Koolen SL, Luyer MD, de Hingh IH, van Laarhoven HW, Mostert B, Wijnhoven BP, Mathijssen RH. **The prognostic value of peritoneal metastases in patients with gastric cancer: a nationwide population-based study.** *EClinicalMedicine.* 2025 Feb 13;81:103109. doi: 10.1016/j.eclinm.2025.103109. eCollection 2025 Mar.

Impactfactor: 10,0

Impactfactor: 10,0

Kamp D, Noya S, Mook S, Ruurda JP, Hillegersberg RV, Wang J, Jeene P, Brosens LA, May AM, [Verhoeven RH](#), Laarhoven HW, Haj Mohammad N. **Incomplete neoadjuvant chemo(radio)therapy**

negatively impacts pathological response and overall survival in locally advanced esophageal cancer. *Eur J Cancer*. 2025 May 31;224:115538. doi: 10.1016/j.ejca.2025.115538. Online ahead of print.

Impactfactor: 7,1

Lansbergen MF, Smith IP, van Alphen EN, Augustinus S, Fransen IJ, Wilmink JW, Besselink MG, Molenaar IQ, Homs MY, de Hingh IH, Bonsing BA, Vos-Geelen J, Haberkorn BC, **Vissers PA**, Nieuwkerk PT, Bijlsma MF, Frederix GW, van Laarhoven HW; Dutch Pancreatic Cancer Group. Patient preferences for pancreatic cancer treatment (PERSEUS): a multicenter discrete choice experiment. *Health Qual Life Outcomes*. 2025 Dec 24;23(1):122. doi: 10.1186/s12955-025-02440-5.

Impactfactor: 3,4

Luyten JA, **van der Geest LG**, Olde Damink SW, Schaap FG, Groot Koerkamp B, Homs MY, Erdmann JI, Brandts WF, Verheij J, Hoogwater FJ, Hagendoorn J, Oor JE, Verdonk RC, Samarska IV, Miclea RL, Bednarsch J, Neumann UP, de Vos-Geelen J, Dewulf MJL; Dutch Hepatocellular and Cholangiocarcinoma Group. Outcomes following exploratory surgery without subsequent resection in perihilar cholangiocarcinoma: a nationwide analysis. *Eur J Surg Oncol*. 2025 Aug 27;51(11):110419. doi: 10.1016/j.ejso.2025.110419. Online ahead of print.

Impactfactor: 2,9

Menso JE, Bruna CL, Ali M, Bonsing B, Bosscha K, Brosens LA, Busch OR, Crobach AS, Daams F, Derksen W, Dewulf MJ, Doukas M, Fariña Sarasqueta A, Festen S, Abu Hilal M, de Hingh IH, Homs MY, Kazemier G, Lips DJ, Luyer MD, de Meijer VE, Mieog JS, Te Riele WW, van Santvoort HC, van der Schelling GP, Stommel M, Verheij J, de Wilde RF, Wilmink JW, Molenaar IQ, Groot Koerkamp B, **van der Geest LG**, Besselink MG. Oncological outcome after robot-assisted versus open pancreatoduodenectomy for upfront resectable cancer in the pancreatic head: a nationwide cohort analysis. *Br J Surg*. 2025 Nov 6;112(11):znaf153. doi: 10.1093/bjs/znaf153.

Impactfactor: 8,8

Muijs CT, Klaver YL, Nuyttens J, Lips IM, Muller K, Ebrahimi GM, Dankers FJ, **Verhoeven RH**, Schuit E, Berbee M. National indication protocol for proton radiotherapy in esophageal cancer patients in the Netherlands. *Radiother Oncol*. 2025 Sep 24:111164. doi: 10.1016/j.radonc.2025.111164. Online ahead of print.

Impactfactor: 5,3

Reijneveld EA, Dronkers JJ, Beijer S, **Velthuis MJ**, Kerst A, Bos S, Warmelink-Galema T, Ruurda JP, Veenhof C; 'PRIOR study group'. Response to a prehabilitation program for patients with oesophageal cancer: an observational study. *Perioper Med (Lond)*. 2025 Dec 19. doi: 10.1186/s13741-025-00633-6. Online ahead of print.

Impactfactor: 2,1

Reijneveld EA, Kooij CD, Dronkers JJ, Kingma BF, Stel JM, Sauer M, van Hillegersberg R, van Duijvendijk P, **Beijer S**, Ruurda JP, Veenhof C; 'PRIOR study group' (**Velthuis MJ**). The course of physical fitness and nutritional status in patients following prehabilitation before esophageal cancer surgery: results from the PRIOR study. *Eur J Surg Oncol*. 2025 Jan 3;51(3):109575. doi: 10.1016/j.ejso.2025.109575. Online ahead of print.

Impactfactor: 2,9

**Slotman E, Pape M**, van Laarhoven HW, Pouw RE, **van der Linden YM, Verhoeven RH Siesling S, Fransen HP, Raijmakers NJ**. Considerations to forgo systemic treatment in patients with advanced esophageal or gastric cancer: a real-world evidence study. *Int J Cancer*. 2025 Jan 9. doi: 10.1002/ijc.35314. Online ahead of print.

Impactfactor: 4,7

Stoop TF, Rompen IF, Ali M, Groot Koerkamp B, Bonsing BA, de Groot JW, Cirkel GA, van Santvoort HC, Verpalen IM, Molenaar IQ, Wilmink JW, de Vos-Geelen J, Daamen LA, Engelbrecht MR, Homs MY, Intven MP, Stommel MW, de Meijer VE, **van der Geest LG**, Besselink MG; Dutch Pancreatic Cancer Group. Resectability stages of pancreatic cancer: nationwide reference. *Br J Surg*. 2025 Jul 3;112(7):znaf120. doi: 10.1093/bjs/znaf120.

Impactfactor: 8,8

Strijbos BT, Kraakman I, Hopstaken JS, van Dongen JC, Janssen QP, van Dam JL, **Akkermans-Vogelaar JM**, Besselink MG, Bonsing BA, Bos H, Bosscha KP, Buijsen J, Busch OR, van Dam RM, Eskens FALM, Festen S, de Groot JW, **Groothuis K**, Haberkorn BC, de Hingh IH, van der Holt B, Homs MY, van Hooft JE, Karsten TM, Kerver ED, van der Kolk MB, van Laarhoven CJ, Liem MS, Luelmo SA, Neelis KJ, Nuyttens J, Paardekooper GM, Patijn GA, van der Sangen MJ, van Santvoort HC, Streppel MM, Suker M, Versteijne E, **Vissers PA**, de Vos-Geelen J, Wilmink JW, Zwinderman AH, van Eijck CH, van Tienhoven G, Groot Koerkamp B, Stommel MW; Dutch Pancreatic Cancer Group. Delayed gastric emptying after pancreatic cancer surgery impacts time to start of adjuvant treatment but not overall survival: a post-hoc analysis of the PREOPANC-1 and -2 trials. *Br J Surg*. 2025 Nov 29;112(12):znaf261. doi: 10.1093/bjs/znaf261. Impactfactor: 5,6

Timmermans QM, de Hingh IH, **Elferink MA**, Wijnhoven BP, Schoon EJ, de Wilt JH, **van der Geest LG**, **Vissers PA**. Trends in resection rates and postoperative mortality for gastrointestinal cancers between 2005 and 2020 in the Netherlands. *Eur J Cancer*. 2025 Apr 25;222:115469. doi: 10.1016/j.ejca.2025.115469. Online ahead of print. Impactfactor: 7,1

Tromp VN, Darsara RA, Crul M, Billings NE, Westerdijk K, Veldt AA, Pieters CS, Westgeest HM, Bleckman RF, Velde IV, Hamberg P, Walraven I, **van den Hurk CJ**, Hugtenburg JG. The usefulness of the ASSUSTENT application and ASSIST brochure in cancer patients using sunitinib. *Cancer Control*. 2025 Jan-Dec;32:10732748251343286. doi: 10.1177/10732748251343286. Epub 2025 May 24. Impactfactor: 2,6

**Truijen SP**, **Vissers PA**, Nieuwenhuijzen GP, van der Sangen MJ, Siersema PD, Slingerland M, Mohammad NH, Beerepoot LV, van Berge Henegouwen MI, van der Sluis PC, Rosman C, Kouwenhoven EA, Aktaş H, van Laarhoven HW, Uyl-de Groot CA, **Verhoeven RH**. A cost-effectiveness analysis of the effect of hospital variation in the probability of providing treatment with curative intent in potentially curable esophageal and gastric cancer patients. *Dis Esophagus*. 2025 Jul 3;38(4):doaf057. doi: 10.1093/dote/doaf057. Impactfactor: 2,3

**van der Geest LG**, **van der Mark M**, Verheij J, Farina Sarasqueta A, de Vos-Geelen J, Besselink MG, de Meijer VE, de Hingh IH, Bonsing BA, de Reuver PR, Willemsen FE, **Vissers PA**, **Visser O**; Dutch Pancreatic Cancer Group and the Dutch Hepatocellular & Cholangiocarcinoma Group. Increased incidence, survival, and registration quality of primary hepato-pancreato-biliary cancers in the Netherlands Cancer Registry. *Int J Cancer*. 2025 Sep 12. doi: 10.1002/ijc.70145. Online ahead of print. Impactfactor: 4,7

van Laarhoven H, **Verhoeven RH**, van Berge Henegouwen M, Mohammad NH, van Hillegersberg R, Slingerland M, Muijs CT, Wijnhoven B, Mostert B, Beerepoot L, Nieuwenhuijzen G, Derks S, van Rossum PS. Real-world outcomes of the CROSS regimen in patients with resectable esophageal or gastro-esophageal junction adenocarcinoma: a nationwide cohort study in the Netherlands. *EClinicalMedicine*. 2025 Jan 22;80:103067. doi: 10.1016/j.eclinm.2024.103067. eCollection 2025 Feb. Impactfactor: 10,0

van Zweeden AA, **van der Geest LG**, Pijnappel EN, de Vos-Geelen J, van Hooft JE, Stommel MW, de Wit GF, Verheul HM, van Laarhoven HW, van der Vliet HJ, Wilmink JW; Dutch Pancreatic Cancer Group. Reintroduction of palliative intent FOLFIRINOX chemotherapy in a real world pancreatic cancer cohort. *Pancreatology*. 2025 Mar 27:S1424-3903(25)00064-X. doi: 10.1016/j.pan.2025.03.011. Online ahead of print. Impactfactor: 2,7

van Zweeden AA, **van der Geest LG**, Wilmink JW. Reply to comments on "Reintroduction of palliative intent FOLFIRINOX chemotherapy in a real world pancreatic cancer cohort". *Pancreatology*. 2025 Jul 25:S1424-3903(25)00156-5. doi: 10.1016/j.pan.2025.07.012. Online ahead of print. Impactfactor: 2,7

**Verhoeven RH**, Kuijper SC, Slingerland M, Wijnhoven B, van Berge Henegouwen MI, van Rossum PS, Derks S, Mostert B, Mohammad NH, van Laarhoven HW. Adjuvant nivolumab after chemoradiotherapy

and resection for patients with esophageal cancer: a real-world matched comparison of overall survival. *Int J Cancer*. 2025 Sep 23. doi: 10.1002/ijc.70168. Online ahead of print.

Impactfactor: 4,7

**Verhoeven RH**, Kuijper SC, Lordick F, Slingerland M, Qin A, van Laarhoven HW. Trastuzumab deruxtecan versus ramucirumab-paclitaxel as second-line therapy for patients with HER2-positive gastric or GEJ adenocarcinoma. *J Natl Compr Canc Netw*. 2025 Sep 11:1-6. doi: 10.6004/jnccn.2025.7058.

Online ahead of print.

Impactfactor: 16,4

Verkolf EM, Dekker EN, **van der Geest LG**, Besselink MG, Bonsing BA, Bruno MJ, Sarasqueta AF, de Hingh IH, Homs MY, Jamieson NB, de Meijer VE, van Velthuysen MF, Verheij J, de Vos-Geelen J, de Wilde RF, Doukas M, Koerkamp BG; Dutch Pancreatic Cancer Group. 10-year survival after resection of pancreatic ductal adenocarcinoma with pathological re-examination of a nationwide cohort. *Eur J Cancer*. 2025 Nov 6;231:116099. doi: 10.1016/j.ejca.2025.116099. Online ahead of print.

Impactfactor: 7,1

Wang HH, Nolte IM, **Verhoeven RH**, Oppedijk V, van Etten B, Kats-Ugurlu G, Plukker JT, Hospers GA. Impact of extending the original criteria in the Chemoradiotherapy for Oesophageal Cancer followed by Surgery Study (CROSS) regimen on treatment outcome in locally advanced esophageal cancer patients. *ESMO Open*. 2025 May 15;10(5):105098. doi: 10.1016/j.esmoop.2025.105098. Online ahead of print.

Impactfactor: 8,3

Wang J, Wu Z, **Verhoeven RH**, Goense L, Mohammad NH, Mook S, van Rossum PS, Slingerland M, Freund JE, Ruurda JP, van Hillegersberg R. A novel TRG-N Prognostic classification system for esophageal cancer undergoing neoadjuvant therapy followed by esophagectomy: a study based on the Netherlands Cancer Registry. *Ann Surg*. 2025 Sep 23. doi: 10.1097/SLA.0000000000006869. Online ahead of print.

Impactfactor: 6,5

Wang J, Wu Z, Goense L, **Verhoeven RH**, Ruurda JP, Hillegersberg RV. Association of waiting time from diagnosis to neoadjuvant chemoradiotherapy on interval distant metastases in esophageal cancer patients: a study based on the Netherlands cancer registry. *Eur J Surg Oncol*. 2025 Sep 17;51(12):110456. doi: 10.1016/j.ejso.2025.110456. Online ahead of print.

Impactfactor: 2,9

## 11.2 Overige publicaties

**Cara I, van 't Hof N**, Siegerink S, Veen L, **Geleijnse G**, van Laarhoven H, **Verhoeven RH**. Automating performance status annotation in oncology using Llama-3. *Stud Health Technol Inform*. 2025 May 15;327:868-869. doi: 10.3233/SHTI250483.

## 11.3 Proefschriften en promoties

Kuiper SC. From data to insight: applying statistical and machine learning methods to real-world data in esophageal and gastric cancer. Amsterdam: Universiteit; 14 oktober 2025. Promotor: HW van Laarhoven. Copromotor: **RH Verhoeven**.

## 12 Urogenitale kanker

### 12.1 Publicaties met impactfactor

Beeren I, Meijer H, van der Heijden AG, **Aben KK**, Witjes JA, Kiemeney LA, Vrieling A. Fluid intake and recurrence and progression risk of patients with non-muscle-invasive bladder cancer. *BJU Int.* 2025 Jan 25. doi: 10.1111/bju.16665. Online ahead of print.  
Impactfactor: 4,5

Beeren I, Kiebach J, Hof JP, Buffart LM, **Aben KK**, Witjes JA, van der Heijden AG, Kiemeney LA, Vrieling A. Physical activity and risks of recurrence and progression among patients with non-muscle invasive bladder cancer. *Int J Cancer.* 2025 Jun 30. doi: 10.1002/ijc.70030. Online ahead of print.  
Impactfactor: 4,7

Brück K, **Atema V**, Leliveld AM, Franckena M, Meijer RP, van der Heijden MS, Donders AR, Witjes JA, de Groot CA, **van Hoogstraten LM**, Kiemeney LA, Boormans JL, **Aben KK**, Hulshof MC; CRAC study group and the BlazIB study group. Health-related quality of life in patients treated for non-metastatic muscle-invasive bladder cancer: radical cystectomy versus bladder preserving therapy. *Int J Radiat Oncol Biol Phys.* 2025 Jul 2:S0360-3016(25)04509-2. doi: 10.1016/j.ijrobp.2025.06.3866. Online ahead of print.  
Impactfactor: 6,5

Dootjes EW, Willeumier JJ, van der Wal CW, van der Wal RJ, van der Zwaal P, Leithner A, van der Veldt AA, Fiocco M, van Broekhoven DL, **van der Linden YM**. Modified OPTIModel with oligometastatic disease for the prediction of overall survival of patients with renal cell cancer and symptomatic long bone metastases. *J Bone Oncol.* 2025 Sep 2;55:100709. doi: 10.1016/j.jbo.2025.100709. eCollection 2025 Dec.  
Impactfactor: 3,5

**Heesterman BL**, Peters M, Oprea-Lager DE, Braat AJ, Schoots IG, Loeff CC, van Leeuwen PJ, van den Bergh RN, Palma DA, **Aben KK**, Eppinga WS. Increased incidence of primary metastatic prostate cancer in the era of PSMA PET/CT: a population-based analysis. *Eur J Nucl Med Mol Imaging.* 2025 Jul 8. doi: 10.1007/s00259-025-07431-8. Online ahead of print.  
Impactfactor: 7,6

Hof JP, Vermeulen S, **Richters A**. Biased associations between number of BCG instillations and outcome in non-muscle-invasive bladder cancer. *BJU Int.* 2025 Jul 24. doi: 10.1111/bju.16866. Online ahead of print.  
Impactfactor: 4,5

Hof JP, Kiemeney LA, **Aben KK**, van der Heijden AG, Vrieling A, Vermeulen SH. Recurrence patterns in a large contemporary cohort of patients with non-muscle invasive bladder cancer. *Clin Genitourin Cancer.* 2025 Nov 4;24(1):102464. doi: 10.1016/j.clgc.2025.102464. Online ahead of print.  
Impactfactor: 2,7

**Nuijens ST, van Hoogstraten LM, Terpstra NB**, Beeren I, Vrieling A, **Wijnen EM**, Meijer RP, Kiemeney LA, Witjes JA, **Aben KK**. The impact of treatment for muscle-invasive bladder cancer on health-related quality of life. *BJU Int.* 2025 Apr 16. doi: 10.1111/bju.16736. Online ahead of print.  
Impactfactor: 4,5

Paulino Pereira LJ, van den Bergh RC, Sedelaar MJ, **Heesterman BL, Aben KK**, Kiemeney L, van Oort I, **van Melick HH**. Risk-based prostate-specific antigen monitoring reduces follow-up burden after radical prostatectomy. *Eur Urol Oncol.* 2025 May 5:S2588-9311(25)00049-5. doi: 10.1016/j.euo.2025.02.013. Online ahead of print.  
Impactfactor: 9,3

Rajwa P, Borkowetz A, Abbott T, Alberti A, Beyer K, Bjartell A, Brash JT, Chilelli A, Davies E, Meulder B, Fazekas T, Golozar A, Hijazy A, Josefsson A, Kasivisvanathan V, Kolde R, Kotik D, Leapman MS, Mischczyk M, Nicoletti R, **Prinsen P**, Remmers S, Ribal MJ, Rivas JG, Rodriguez-Sanchez L, Roobol MJ, Smith E, Snijder R, Steinbeisser C, Stroomberg HV, Gandaglia G, Cornford P, Evans-Axelsson S, N'Dow J, Willemsse PM; PIONEER Consortium. Observational health data analysis of the cardiovascular adverse events of systemic treatment in patients with metastatic hormone-sensitive prostate cancer: big data

analytics using the PIONEER Platform. *Eur Urol Focus*. 2025 Oct 3:S2405-4569(25)00251-2. doi: 10.1016/j.euf.2025.08.005. Online ahead of print.  
Impactfactor: 5,6

**Richters A**, Suelmann B, Franken M, Mehra N, Rikhof B, Westgeest H, **Aben KK**, Robbrecht D; ProBCI Study Group. Pembrolizumab after platinum-based chemotherapy for metastatic urothelial cancer: comparison between patients from a Dutch nationwide cohort and KEYNOTE-045. *Cancer Treat Res Commun*. 2025 Apr 15;43:100931. doi: 10.1016/j.ctarc.2025.100931. Online ahead of print.  
Impactfactor: 2,4

Ugalde-Morales E, Wilf R, Pluta J, Ploner A, Fan M, Damra M, **Aben KK**, Anson-Cartwright L, Chen C, Cortessis VK, Daneshmand S, Ferlin A, Gamulin M, Gietema JA, Gonzalez-Niera A, Grotmol T, Hamilton RJ, Harland M, Haugen TB, Hauser R, Hildebrandt MAT, Karlsson R, Kiemeny LA, Kim J, Lessel D, Lothe RA, Loveday C, Chanock SJ, McGlynn KA, Meijer C, Nead KT, Nsengimana J, Popovic M, Rafnar T, Richiardi L, Rocca MS, Schwartz SM, Skotheim RI, Stefansson K, Stewart DR, Turnbull C, Vaughn DJ, Winge SB, Zheng T, Monteiro AN, Almstrup K, Kanetsky PA, Nathanson KL, Wiklund F; Testicular Cancer Consortium. Identification of genes associated with testicular germ cell tumor susceptibility through a transcriptome-wide association study. *Am J Hum Genet*. 2025 Mar 6;112(3):630-643. doi: 10.1016/j.ajhg.2025.01.022. Epub 2025 Feb 24.  
Impactfactor: 8,1

**van der Starre CM**, **Aben KK**, van Leeuwen PJ, Busstra MB, Scheltema MJ, Bruins MH, Roelink H, van der Poel HG, de Jong IJ, **Heesterman BL**, Somford DM. Evaluation of short term surgical outcomes of radical prostatectomy in the decade following the introduction of minimum volume standards in the Netherlands. *Urol Oncol*. 2025 Apr 21:S1078-1439(25)00119-X. doi: 10.1016/j.urolonc.2025.03.020. Online ahead of print.  
Impactfactor: 2,3

**van der Starre CM**, Bangma CH, **Bijlsma MJ**, van den Bergh AC, Kiemeny LA, Kievit W, Vos K, Somford DM, Wildeman SM, **Aben KK**, de Jong IJ, Pos FJ, **Heesterman BL**. External beam radiation therapy versus radical prostatectomy for high-risk prostate cancer: protocol of the RECOVER study. *BMC Cancer*. 2025 Jan 27;25(1):149. doi: 10.1186/s12885-025-13511-7.  
Impactfactor: 3,4

van Doeveren T, Remmers S, Boevé ER, Cornel EB, van der Heijden AG, Hendricksen K, Cauberg EC, Jacobs R, Kroon BK, Leliveld AM, Meijer RP, van Melick H, Merks B, Oddens JR, Pradere B, Roelofs LA, Somford DM, de Vries P, Wijsman B, Windt WA, Yska M, Zwaan PJ, **Aben KK**, van Leeuwen PJ, Boormans JL. Intravesical instillation of chemotherapy before radical surgery for upper urinary tract urothelial carcinoma: the REBACARE Trial. *Eur Urol*. 2025 Jan 21:S0302-2838(24)02759-3. doi: 10.1016/j.eururo.2024.12.006. Online ahead of print.  
Impactfactor: 25,2

van Doeveren T, **Aben KK**, van Leeuwen PJ, Boormans JL. Reply to Alexandra Masson-Lecomte. Bladder cancer recurrence following management of upper tract urothelial carcinoma: balancing prevention and iatrogenicity. *Eur Urol*. In press. <https://doi.org/10.1016/j.eururo.2025.01.004>. *Eur Urol*. 2025 Mar 17:S0302-2838(25)00151-4. doi: 10.1016/j.eururo.2025.02.028. Online ahead of print.  
Impactfactor: 25,2

van Doeveren T, **Aben KK**, van Leeuwen PJ, Boormans JL. Reply to Malshy et al, Vanthoor et al, and Ye et al. Letters to the editor re: Thomas van Doeveren, Sebastiaan Remmers, Egbert R. Boevé, et al. Intravesical instillation of chemotherapy before radical surgery for upper urinary tract urothelial carcinoma: the REBACARE trial. *Eur Urol*. 2025 Jun 17:S0302-2838(25)00347-1. doi: 10.1016/j.eururo.2025.06.004. Online ahead of print.  
Impactfactor: 25,2

Vrieling A, Olsson LT, Kleuters G, Maurits JS, **Aben KK**, Sedelaar JP, Furberg H, Kiemeny LA. Pre- and post-diagnosis body weight trajectories in patients with localized renal cell cancer. *Cancer Causes Control*. 2025 Jan 6. doi: 10.1007/s10552-024-01957-2. Online ahead of print.  
Impactfactor: 2,1

**Yildirim H, Aben KK, Bijlsma MJ**, Postema AW, Aarts MJ, van Oijen MG, Bex A, Bins AD, Zondervan PJ. A nationwide real-world evaluation of upfront cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma in the immunotherapy era. *Eur Urol Oncol.* 2025 Apr 11:S2588-9311(25)00044-6. doi: 10.1016/j.euo.2025.02.011. Online ahead of print.  
Impactfactor: 9,3

**Yildirim H, Richters A**, Bins AD, Postema AW, Aarts MJ, van Oijen MG, Zondervan PJ, **Aben KK**. Immunotherapy in metastatic renal cell carcinoma: insights from a Dutch nationwide cohort. *Eur Urol Open Sci.* 2025 Feb 10;72:42-45. doi: 10.1016/j.euros.2025.01.008. eCollection 2025 Feb.  
Impactfactor: 4,5

**Yildirim H, Schuurman MS, van Melick HH**, Bins AD, Zondervan PJ, **Aben KK**. Trends in treatment and survival of older vs younger patients with renal cancer between 2011 and 2022. *BJU Int.* 2025 Dec 23. doi: 10.1111/bju.70116. Online ahead of print.  
Impactfactor: 4,5

### 12.3 Proefschriften en promoties

van Doeveren T. Upper urinary tract urothelial carcinoma: unravelling the molecular background and clinical dilemmas. Rotterdam: Erasmus Universiteit; 12 november 2025. Promotor: JL Boormans.  
Copromotoren: **KK Aben**, PJ van Leeuwen.

## B1 Impactfactoren tijdschriften

**Tabel 1** Overzicht tijdschriften met impactfactor

<i>Naam tijdschrift:</i>	<i>Impactfactor:</i>	<i>Aantal publicaties:</i>
AJHG American Journal of Human Genetics	8,1	1
American Journal of Epidemiology	4,8	1
Annals of Epidemiology	3,0	1
Annals of Surgery	6,5	1
Annals of Surgical oncology	3,5	3
BJD British Journal of Dermatology	10,6	1
BJHaem British Journal of Haematology	3,9	2
BJN British Journal of Nutrition	3,0	1
BJS British Journal of Surgery	8,8	4
BJU international	4,5	4
Blood Advances	7,1	2
Blood Cancer Journal	11,6	1
BMC Cancer	3,4	2
BMC Health Services Research	3,0	1
BMC Palliative Care	3,0	2
BMJ Health & Care Informatics	4,4	1
BMJ Open	2,3	1
Brain Imaging and Behavior	2,4	1
Breast Cancer Research	5,6	1
Breast Cancer Research and Treatment	3,0	3
Cancer, causes & control	2,1	1
Cancer Control	2,6	1
Cancer Epidemiology	2,3	4
Cancer Medicine	3,1	3
Cancer Treatment and Research Communications	2,4	2
Cancers (Basel)	4,4	4
Cardio-oncology	3,2	1
Chemotherapy	1,7	1
Clinical Breast Cancer	2,5	1
Clinical Cancer Research	10,2	1
Clinical Colorectal Cancer	3,2	3
Clinical Genitourinary Cancer, prostate, kidney & bladder	2,7	1
Clinical Lymphoma, Myeloma and Leukemia	2,7	1
Clinical Nutrition ESPEN	2,6	1
Clinical Otolaryngology	1,5	1
Cochrane Database of Systematic Reviews	9,4	1
Colorectal Disease	2,7	2
ctRO Clinical and Translational Radiation Oncology	2,7	1
Current Oncology	3,4	1
Diseases of the esophagus	2,3	1
eClinicalMedicine	10,0	4

EJC European Journal of Cancer	7,1	19
EJOG Eur. Jour. of Obstetrics&Gyneecology and Rep. Biol.	1,9	1
EJSO European Journal of Surgical Oncology	2,9	6
Endoscopy	12,8	1
ESMO Open	8,3	4
European Journal of Epidemiology	5,9	2
European Journal of Haematology	2,3	1
European Journal of Nuclear Medicine and Molecular Im.	7,6	1
European Journal of Oncology Nursing	2,7	1
European Radiology	4,7	1
European Urology	25,2	3
European Urology Focus	5,6	1
European Urology Oncology	9,3	2
European Urology Open Science	4,5	1
Experimental Dermatology	3,1	1
Familial Cancer	2,0	1
Frontiers in Health Services	2,7	1
Gynecologic Oncology	4,1	2
Gynecologic Oncology Reports	1,3	1
Haematologica	7,9	2
Head & Neck	2,2	1
Health and Quality of Life Outcomes	3,4	1
Health Communication	2,7	1
Health Expectations	3,2	1
Health Psychology Review	9,7	1
Healthcare	2,7	1
Hematological Oncology	3,9	1
Histopathology	4,1	1
HPB (Oxford)	2,4	1
Human Genomics	4,3	1
IJC International Journal of Cancer	4,7	15
International Journal of Epidemiology	5,9	1
International Journal of Gynecological Cancer	4,7	3
International Journal of Radiation, Oncology, Biol.,Phys.	6,5	1
iScience	4,1	1
JAAD Journal of the American Academy of Dermatology	11,8	2
JCO Global Oncology	3,3	1
JCO Journal of Clinical Oncology	43,4	1
JCO Oncology Practice	4,7	2
JCO Precision Oncology	5,8	1
JGO Journal of Gynecologic Oncology	3,7	1
JMIR AI	2,0	1
JMIR Cancer	2,7	1
JMIR Formative Research	2,1	1
JMIR Journal of Medical Internet Research	6,0	2
JNCCN Journal of the Nat. Comp. Canc. Netw.	16,4	1
JNCI Journal of the National Cancer Institute	7,2	3
Journal of Bone Oncology	3,5	1
Journal of Cancer Education	1,3	1

Journal of Cancer Policy	2,0	1
Journal of Cancer Survivorship	2,9	7
Journal of Clinical Epidemiology	5,2	2
Journal of Infectious Diseases	4,5	1
Journal of Neuro-Oncology	3,1	3
Journal of Palliative Medicine	2,1	1
Journal of Patient-Reported-Outcomes	2,9	1
Journal of the National Cancer Center	9,4	1
Leukemia & Lymphoma	2,2	1
Lung Cancer	4,4	3
MDM Policy & Practice	1,7	1
Nature	48,5	1
npj Breast Cancer	7,6	2
Oral Oncology	3,9	1
OJRD Orphanet Journal of Rare Disease	3,5	1
Palliative and Supportive Care	2,1	1
Palliative Medicine	3,9	2
Palliative Medicine Reports	1,3	1
Pancreatology	2,7	2
Perioperative Medicine	2,1	1
Plos One	2,6	3
Psycho-Oncology	3,5	1
Quality of Life Research	2,7	1
Radiation Oncology	3,2	1
Radiotherapy & Oncology	5,3	2
Scientific Reports	3,9	1
Sleep Medicine	3,4	1
Social Science & Medicine	5,0	1
Statistics in Medicine	1,8	1
Supportive Care in Cancer	3,0	9
Technical Innovations & Patient Support in Radiation Onc.	2,8	1
The Breast	7,9	6
The Lancet	88,5	1
The Lancet Child & Adolescent Health	15,5	1
The Lancet Digital Health	24,1	1
The Lancet Oncology	35,9	1
The Lancet Public Health	25,2	1
The Lancet Regional Health Europe	13,0	2
Therapeutic Advances in Medical Oncology	4,2	1
Urologic Oncology: seminars	2,3	1

**Tabel 2** Overzicht tijdschriften zonder impactfactor

BMJ Public Health	1
Measurement and evaluations in cancer care	1
NtvG	3
Studies in Health Technology and Informatics	3

Integraal Kankercentrum  
Nederland  
info@iknl.nl  
www.iknl.nl

